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1. INTRODUCTION 
 
 
 
This study  is focused on pUL50 and pUL53, two genic products of Human Cytomegalovirus, 
whose homologs in the Herpesviridae family are described as essential for viral maturation, 
and on the alterations of cellular components in which the two viral proteins are supposed to 
be involved.  
 
 
1.1 HUMAN CYTOMEGALOVIRUS: GENERALITIES 
 
Human  Cytomegalovirus  (HCMV)  belongs  to  the  family  Herpesviridae,  subfamily  β-
Herpesvirinae [1].  
HCMV  shares  many  characteristics  with  other  herpsviruses,  including  virion  and  genome 
structure and the ability to estabilish persistent and latent infections, but presents also distinct 
characteristics, such as tropism for macrophages and endothelial cells in vivo, high species 
specificity and slow growth in cell culture on epithelial cells and fibroblasts [2].  
 
 
1.1.1 Epidemiology 
 
Cytomegalovirus  is  easily  transmitted,  usually  through  contact  with  bodily  fluids  or  by 
placental transfer. Seroprevalence rates vary by socioeconomic class and geographic location, 
but the overall seroprevalence in developed countries is estimated to be in the range of 30–
70% [3].  
Primary infection in immunocompetent individuals is usually benign, with minimal or no 
clinical manifestations (although approximately 10% of mononucleosis syndromes are a result 
of CMV infection). Following primary infection, the virus establishes latency, and viremia is 
mainly  controlled  by  cell-mediated  immunity.  A  virus  reactivation  can  occur  when  the   2
protective immune surveillance fails, for example, as a result of chemotherapy or in patients 
who have AIDS or who are immunosuppressed for transplantation purposes; such reactivation 
or primary infection in the context of a disabled immune system can lead to overt disease.  
In the case of vertical transmission of CMV, from the mother to the developing fetus, adverse 
outcomes  are  most  commonly  associated  with  primary  infection  of  the  mother,  although 
significant morbidity has also been associated with secondary infection. 
- Congenital HCMV infection. One of the most important clinical manifestations of primary 
human cytomegalovirus infection is seen in newborn babies infected during pregnancy[4]. In 
a seronegative mother, the risk of primary infection is 0,7–4,1%, which carries a 40% risk of 
congenital  infection[5].  The  risk  to  the  infant  is  greatest  if  infection  occurs  in  the  first 
trimester,  since  maternal  cytomegalovirus  antibodies  have  a  protective  role  against 
intrauterine  transmission  (but  not  against  development  of  symptoms  once  infection  has 
arisen)[6]. Results of studies on infants with asymptomatic infection indicate that 10–17% 
develop  hearing  defects  or  neurodevelopmental  sequelae.  More  importantly,  5–10%  of 
congenitally infected neonates have symptoms of irreversible CNS involvement in the form of 
microcephaly, encephalitis, deafness (a solitary finding in 10% of cases), upper motor neuron 
disorders, psychomotor retardation, and, rarely, myopathy and choroidoretinitis[7]. Findings 
of long-term follow-up studies indicate that most affected infants (up to 80%) display serious 
life-long neurological abnormalities with severe life-threatening organ dysfunction and death 
in 10–20% of patients. 
- Perinatal infection. Cytomegalovirus infection can also be acquired perinatally, which is 
generally asymptomatic. However, up to 30% of perinatally infected infants display short-
term,  self-limiting  symptoms  of  hepatosplenomegaly,  lymphadenopathy,  hepatitis,  or 
pneumonia; neurological sequelae or hearing impairment does not typically arise with this 
mode of infection. 
- Infection of transplant recipients. CMV infection is the leading cause of morbidity and 
mortality for patients who receive solid organ or bone marrow transplantations. The most 
important  risk  factor  for  the  development  of  CMV  disease  in  transplant  recipients  is  the 
donor’s seropositivity coupled with seronegativity of the recipient [8]. Although definitive 
proof  is  lacking,  the  degree  of  viral  load  within  the  transplanted  organ  is  probably 
proportional to risk of subsequent disease. Even secondary infection in a seropositive patient, 
due to reactivation or super-infection, may lead to CMV disease during immunosuppression, 
although the risk is substantially smaller and the disease generally less severe. 
   3
1.1.2 Antiviral treatment 
 
Currently  available  drugs  consist  of  molecules  able  to  block  the  viral  replication,  mainly 
inhibiting the replication of viral genome. By now the most effective drugs are the nucleoside 
analog gancyclovir[9], the nucleotide analog cidofovir [10] and the pyrophosphate analog 
foscarnet [11] , which have been licensed for serious for life-threatening HCMV infections in 
immunocompromised individuals. These drugs have produced clinical improvement in many 
patients, but suffer from poor oral bioavailability, low potency, development of resistance in 
clinical practice and dose-limiting toxicities. 
−  Gancyclovir (GCV) is a competitive inhibitor of viral DNA polymerase (pUL54) and 
its antiviral activity requires monophosphorylation in the infected cell by the HCMV 
encoded  phosphotransferase  pUL97,  followed  by  diphosphorylation  by  cellular 
kinases[12]. It is usually the front-line drug for the treatment of HCMV infections; 
however,  the  emergence  of  GCV  resistant  strains  due  to  UL97  and  UL54  gene 
mutations [13], mainly in patients during prolonged maintenance therapy, such as in 
AIDS  patients    and  less  frequently  in  solid  organ  transplant  recipients,  is  well 
documented. 
−  Cidofovir (CDV) is a competitive inhibitor of the HCMV DNA polymerase and has 
been approved for the treatment of HCMV retinitis. One of its advantages compared 
with GCV is its long intracellular halflife. Cross-resistance between GCV and CDV 
could become a concern since they share the same target, the product of the UL54 gene.  
−  Foscarnet (PFA) is a non-competitive inhibitor of the pyrophosphate binding site of 
HCMV DNA polymerase, which does not require prior activation by a virally encoded 
enzyme. It is administered as an alternative to GCV in the event of GCV resistance or 
severe side-effects, but even long-term exposure to PFA may lead to the emergence of 
resistant strains due to UL54 mutations. 
Double resistance to GCV and PFA in strains from AIDS patients has been reported and high-
level GCV-resistant strains with both UL97 and UL54 mutations were found to be cross-
resistant  to  CDV.  The  emergence  of  HCMV  strains  resistant  to  these  conventional  drugs 
induces continuously to the development of new antiviral formulation directed against new 
targets. An antisense oligonucleotide against the HCMV IE2 mRNA, called Fomivirsen, has 
also been developed for intravitreal applications in patients with retinitis who do not respond 
to conventional management; moreover, a promising new class of anti-HCMV compounds,   4
formed of benzimidazole ribosides, which do not inhibit the viral DNA polymerase is object 
of study. 
 
 
1.1.3 Virus structure 
 
The virion of HCMV consists of a 100-nm diameter icosahedral nucleocapsid containing a 
230-kbp, double stranded linear DNA genome surrounded by a proteinaceous layer defined as 
the  tegument  or  matrix,  which,  in  turn,  is  enclosed  by  a  lipid  bilayer,  called  envelope, 
containing a large number of viral glycoproteins. The mature virion particle is 150–200 nm in 
diameter (Fig. 1.1) .  
- Capsid. Of the more than 30 viral proteins found in the complete infectious virion, four 
constitute the capsid: namely, pUL46, pUL48.5, the minor capsid protein (mCP), and the 
major  capsid  protein  (MCP)  encoded  by  UL85  and  UL86,  respectively.  Three  assembly 
proteins encoded by UL80 associate with capsid and play roles in maturation. The capsid 
contains the single copy of highly packed DNA genome and two poyamines, spermine and 
spermidie, which likely counteract the negative charge of packaged DNA. 
- Tegument or matrix. This amorphous layer between the nucleocapsid and the envelope is 
still  poorly  characterized  [14]  and  contains  about  20-25  structural  proteins  that  may  be 
involved in the maturation of progeny virions or may influence viral and cellular events  in 
the early stages of infection, such as release of viral DNA from disassembling virus particles 
or the regulation of viral and cellular promoters. Most tegument proteins are phosphorylated 
and  are  highly  immunogenic.  The  most  abundant  are  ppUL32  (pp150  or  basic 
phosphoprotein) and ppUL83 (or pp65),which, due to its large amounts, has been chosen as 
the target antigen in rapid diagnosis assays. Other tegument proteins, such as ppUL69 and 
ppUL82  (pp71),  may  play  important  regulatory  roles  in  both  viral  and  cellular  gene 
expression, acting as transactivators of viral gene expression and dysregulating the cell cycle 
progression [15], [16], [17], [18]. 
- Envelope. The phospholipid envelope originates from the cellular membrane of the host 
cells and contains at least 8 viral glycoproteins, 6 of which associate to form three highly 
conserved complexes designated as gCI, gCII, and gCIII [19]: 
−  gCI, composed of homodimeric gB molecules (gpUL55), plays a crucial role in virus 
binding and participates in viral entry, cell-to-cell spread, and cell fusion;   5
−  gCII results from the association of gM (gpUL100) and gN (gpUL73). It is the most 
abundant protein complex on the viral envelope and is involved in the adesion to the 
host cell binding to heparan sulfate proteoglycans; 
−  gCIII, a heteroligomeric complex composed of gH, gL, and gO [20], is necessary for 
the final stage of virus entry via pH-independent fusion between the viral envelope and 
the cell membrane  [21]. 
A number of abundant host cell protein, including 2-microglobulin, actin and several cellular 
enzymes  were  found  to  associate  with  purified  virions,  suggesting  a  role  during  HCMV 
infection. 
 
 
1.1.4 Viral life cycle 
 
HCMV replicative cycle reflects the typical viral cycle of Herpesviruses. Four main phases 
can be distinguished (Fig.1.2): 
 
a) Virus attachment and penetration 
Virus  attachment  and  penetration  are  rapid  and  efficient  in  both  permissive  and  non-
permissive cell types. However, since productive replication is observed in a very restricted 
range of human cells, a post-penetration block to viral gene expression is thought to restrict 
replication in nonpermissive cells [22]. The poorly characterized receptor(s) for HCMV is 
widely distributed among host cell types, and contributes to the broad viral tropism observed 
during natural infections. Viral entry is the result of a cascade of interactions between viral 
and cellular proteins that culminate in fusion of the virion envelope with the cellular plasma 
membrane  by  a  pH-independent  mechanism.  During  the  initial  virus-cell  interactions,  as 
observed with other herpesviruses, HCMV attaches to the cell surface by low-affinity binding 
of gB to heparan sulfate proteoglycans [23]. The subsequent interaction of gB with its non-
heparin receptor then turns the weak adhesion of the viral particle into a more stable binding 
or docking state. However, final fusion of the viral envelope with the cell membrane to allow 
viral penetration is thought to require a further priming event mediated by the heteroligomeric 
gH-gL-gO  complex  with  as  yet  unidentified  receptors  [20].  Fusion  of  the  virus  and  cell 
membranes is followed by entry into the host cytoplasm of the nucleocapsid and tegument 
proteins, and their rapid translocation into the nucleus. Interaction of HCMV glycoproteins   6
with their receptors is enough to generate an intracellular signal transduction pathway, leading 
to the alteration of cellular gene expression. 
 
b) Viral gene expression 
During productive infection, the HCMV genome is expressed in a temporally coordinated and 
regulated cascade of transcriptional events that lead to the synthesis of three categories of 
viral proteins described as immediate-early (IE or α), early (E or β), and late (L or γ). Failure 
in the expression of early gene and subsequent viral DNA replication rather than attachment 
and/or  penetration  may  be  the  restricting  event  in  nonpermissive  cells.  HCMV  genes  are 
transcribed  in  the  infected  cell  nucleus  by  RNA  polymerase  II  and  the  associated  basal 
transcription machinery, with the intervention of host-encoded transcription factors whose 
activity may be stimulated by viral transactivators [24], [25]. 
−  Immediate-Early  genes  (IE  or  α).  HCMV  gene  expression  initiates  from  a  few  IE 
proteins within l hr p.i. without de novo protein synthesis. The IE genes include the 
major IE (MIE) UL122/123 genes (IE1 and IE2) and auxiliary genes, such as UL36–
UL38, UL115–UL119, IRS1/TRS1, and US3. The MIE proteins, alone or in synergism, 
are required for subsequent expression by acting as transactivators and autostimulators 
of viral genes. In addition, these proteins have a deep impact on host cell physiology 
since they regulate the expression of a large number of host cell genes [24]. 
−  Early genes (E or β). Expression of E or β genes depends on the presence of functional 
IE proteins and is unaffected by  inhibitors of viral DNA replication [24]. They are 
divided into two subclasses: β1 (E) and β2 (E-L) according to their time of expression. 
The  functional  data  indicate  that  E  genes  encode  mostly  non-structural  proteins, 
including  viral  DNA  replication  factors,  repair  enzymes,  and  proteins  involved  in 
immune evasion [26]. Several E genes, such as UL4, UL44, UL54, and UL112/113, are 
also transcribed late in infection through several mechanisms, including activation of a 
promoter different and independent from that transcriptionally active in the E times, 
initiation of transcription from a new start site, and alteration of the splicing pattern as 
infection proceeds [24, 26]. Both E and L transcripts may have a polycistronic structure 
due to the relatively few polyadenylation signals in the genome that generate families 
of 30 co-terminal transcripts. In addition, expression of several E genes studied in some 
detail is regulated by both transcriptional and post-transcriptional mechanisms [26]. 
−  Late genes (L or γ). The L proteins are the last class of gene products expressed during 
HCMV replication. Their transcription begins more than 24 hr p.i. and requires prior   7
viral DNA replication [24]. Late or γ gene expression leads to the synthesis of two 
subclasses of L proteins (g1 and g2) in accordance with their time of expression and 
sensitivity to viral DNA replication inhibitors. g1 (leaky late) transcription occurs 24–
36 hr p.i., and is reduced by such inhibitors. g2 (true late) transcription occurs 24–48 hr 
p.i.,  and  is  strictly  dependent  on  DNA  replication.  The  L  proteins  have  mainly 
structural  roles  and  primarily  contribute  to  the  assembly  and  morphogenesis  of  the 
virion[26]. 
 
c) Viral DNA replication 
HCMV genome replication, inversion, and packaging occur in the nucleus of the infected 
cells. Viral DNA synthesis, that begins later than 16 hr p.i., requires the activities of essential 
and specific viral proteins and the active contribution of several cellular proteins [26]. 
Unlike  other  herpesviruses,  HCMV  does  not  encode    deoxyribonucleotide  biosynthetic 
enzymes, such as thymidine kinase, dihydrofolate reductase, thymidylate synthase, and an 
active form of ribonucleotide reductase [27, 28]. Thus, the virus must depend on the host cell 
metabolism to ensure a sufficient supply of dNTPs for its DNA replication. As a result, it does 
not  shut  off  host  macromolecular  synthesis,  but  stimulates  cellular  transcription  and 
translation. 
Six herpesvirus-conserved ORFs in the HCMV genome provide the core replication proteins 
for viral DNA replication: among them, the single-stranded DNA-binding protein ppUL57 
prevents  the  reannealing  of  DNA  strands  following  unwinding  by  the  helicase-primase 
complex, made of three subunits (pUL70, pUL102, pUL105); the DNA polymerase encoded 
by UL54 and the DNA polymerase processivity factor UL44 that prevents dissociation of 
UL54 from the template (Griffiths, 2000; [26]. HCMV DNA replication proceeds through 
initial circularization of the input genome within 4 hr p.i., followed by DNA synthesis via a 
bidirectional ө mechanism from a single origin (oriLyt) of replication that undergoes a switch 
to a late-phase rolling circle form of DNA replication [26]. Packaging of the genome into 
preformed  capsids  then  follows  its  cleavage  at  the  essential  highly  conserved 
cleavage/packaging signals (pac1 and pac2). 
 
d) Virion assembly, maturation, and egress 
Formation of HCMV capsids and packaging of viral DNA occur in the nucleus. Subsequently, 
nucleocapsids  acquire  a  primary  envelopment  by  budding  at  the  nuclear  membrane,  and 
further  mature  through  a  de-envelopment/reenvelopment  process  in  the  cytoplasm  before   8
leaving the cell via an exocytotic-like pathway [26, 29]. Nucleocapsid particles accumulate in 
inclusions  that  confer  the  typical  ‘‘owl’s  eye’’  appearance  of  the  infected  cell  nucleus. 
Capsids are initially enwrapped through budding at the nuclear membrane, where they acquire 
a primary envelope derived from its inner leaflet [30]. They then cross the lumen, fuse with 
the outer leaflet of the nuclear membrane or the ER membrane with which it is contiguous, 
lose  their  primary  envelope,  and  move  into  the  cytoplasm.  Here,  HCMV  virion  particles 
further  mature  by  acquiring  their  tegument.  The  tegumented  capsids  then  receive  their 
definitive envelope by budding into vesicles of the Golgi apparatus [31]. Both tegumentation 
and reenvelopment are driven by multiple specific protein-protein interactions to secure the 
integrity of the viral particle [29]. These mature particles are retained within the vesicles and 
transported  to  the  cell  surface  via  the  Golgi  network,  which  is  enlarged  due  to  the 
accumulation of nucleocapsids and DB. The Golgi alterations during 
the late replication stages create inclusions around the nucleus that result in its characteristic 
kidney-like appearance [3]. Progeny virus accumulates in the cytoplasm, and infectious virus 
is released into the extracellular compartment beginning at 72 hr p.i. In the very late stages, 
however, a substantial number of viral particles are still associated with the cell. 
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1.2  NUCLEAR  ENVELOPE  AND  NUCLEAR  LAMINA:  STRUCTURE  AND 
IMPAIRMENT DURING VIRAL INFECTION 
 
The nuclear envelope (NE) is composed of three distinct elements: the nuclear membrane, 
nuclear pore complexes and the nuclear lamina [32] (Fig. 1.3). The nuclear membrane is a 
double-unit lipidic layer, in which the outer nuclear membrane (ONM) is continuous with and 
shares  biochemical  and  functional  properties  with  the  endoplasmic  reticulum  (ER).  In  
contrast, the inner nuclear membrane (INM) is distinct from both the ER and ONM, from 
which is separated by a narrow lumen, called perinuclear space and is defined by a subset of 
integral membrane proteins, termed nuclear envelope transmembrane proteins (NETs), that 
are anchored to the INM during interphase [33]. These inner membrane proteins, whose major 
members are emerin, lamin B receptor (LBR), lamin-associated-polypeptide (LAP)1 and 2 
and MAN-1, are arranged with their N-termini facing the nucleoplasm and are modified by 
various  kinases.  In  addition,  nearly  all  of  them  associate  with  the  nuclear  lamina  and/or 
chromatin and possess hydrophilic end-domains that can drive non-nuclear proteins to the 
nuclear envelope [34]. 
The  nuclear  membrane  is  punctuated  by  nuclear  pore  complexes  (NPCs),  large  protein 
structures of about 125 MegaDaltons (MDa) which regulate the passage of  macromolecules 
between the nucleus and the cytoplasm [35]. In principle, molecules of 60 kDa can diffuse 
freely across the NPC; however, in reality, the trafficking of several such molecules is tightly 
controlled  [36].  In  general,  the  nuclear/cytoplasmic  trafficking  is  highly  regulated  and 
proteins to be imported or exported from the nucleus contain either a nuclear localization 
signal (NLS) or nuclear export signal (NES), which is  recognized by a receptor and carried 
through  the  NPC  (Fig.  1.4)[37].  Once  in  the  correct  compartment,  the  protein  cargo  is 
released and the receptor recycled for another round of transport. The transport involves a 
small Ras-like GTPase, called Ran, crucial to maintain the direction of transport, establishing 
a  gradient  essential  for  nuclear  transport  in  which  RanGTP  accumulates  in  the  nucleus. 
Members of a growing family of transport receptors carry proteins into and out of the nucleus 
and bind preferentially to Ran in its GTP-bound form. For protein export, the exportin CRM1 
forms  a  complex  with  the  NES-containing  cargo  and  RanGTP  in  the  nucleus.  Once  the 
complex  is  translocated  into  the  cytoplasm,  hydrolysis  of  RanGTP  to  RanGDP  occurs, 
causing the NES containing cargo to be released. The function of CRM-1 has been discovered 
contemporarly to its inhibitor, Leptomycin B [38, 39, 40, 41], an unsaturated branched-chain 
fatty acid that specifically blocks the association NES-CRM-1, binding covalently CRM1, at   10
very low molarity [42] and preventing the association with NES-containing proteinsm(Fig. 
1.5). 
For the nuclear import of many NLS-containing proteins, the adaptor protein, importin α, 
recognizes and binds the NLS-containing cargo (Fig. 1). The import receptor, importin β, can 
then bind to importin α, and this complex translocates across the nuclear envelope through the 
NPC. Once in the nucleus, RanGTP preferentially binds to importin β, causing the release of 
the NLS-containing cargo (Fig. 1.4). Many proteins for import are not rerecognized by the 
importin-α or -β receptor, but are recognized by other receptors related to importin β. There 
are at least 21 potential importin β family members in humans[43]. 
Underneath the INM is the nuclear lamina, a 10 to 50 nm thick meshwork of proteins, whose 
major components are members of the lamin family of type V intermediate filament (IF) 
proteins, called lamins [44] . 
Humans have three distinct lamin genes encoding seven different proteins that, based on their 
expression pattern, properties and location, can be divided in two broad classes (Fig: 1.6b):  
−  B-type lamis are encoded by two different genes: LMNB1 originates lamin B1 which is 
ubiquitous [45] and LMNB2 has two alternatively spliced products, lamin B2 expressed 
in most cells[46] and B3 expressed only in spermatocytes [47]. Expression of B-type 
lamins is essential for nuclear integrity, cell survival and normal development [48, 49, 
16] and , for these reasons,  they are considered fundamental building blocks of the 
nuclear lamina. 
−  A-type lamins are all alternatively spliced products of a single gene, termed LMNA.  
Four different proteins have been described: lamin A and C are the major products in 
most differentiated cells [44] and differ the C-terminal domain as lamin C lacks of the 
last 90 aminoacids; lamin A∆10 is a lamin A variant with a 30-aminoacid deletion 
within the C-terminal domain and it is found in tumor and normal cell lines; lamin C2 
is  germline  specific  product.  In  contrast  with  B-type  lamins  ,  A-type  lamins  are 
differentially  expressed,  their  appearance  in  any  cell  type  is  correlated  with 
differentiation [50, 46, 51, 52] and are dispensable for development, suggesting more 
specialized functions [53] 
Lamins  share  a  common  primary  sequence  consisting  of  globular  N-terminal  domain,  a 
central rod domain, divided in four a-helical segments and a globular C-terminal domain, 
containing a nuclear localization signal (NLS) (Fig. 1.6a). Through coiled-coil association of 
the a-helical rod domains, lamins are able to form parallel homodimers[54], which, in turn,   11
associate  longitudinally  in  head-to-tail  tetramers  [55,  56,  57],  whose  further  anti-parallel 
association originates lamin filaments[58]. 
Post-translational modification of the head and tail domains of lamins is required to control 
lamin assembly. First of all, lamins have to be processed correctly: all lamins other than lamin 
C contain a COOH-terminal motif comprising a cysteine, two aliphatic amino acids, and any 
COOH-terminal amino acid, termed a CaaX box. This motif is the target for a sequence of 
modifications  that  lead  to  isoprenylation  and  methylation  of  the  COOH-terminal  cysteine 
residue. Addition of a 15-carbon farnesyl isoprenoid to the cysteine occurs initially within the 
nucleoplasm, and this is followed by proteolytic cleavage of the aaX [53, 59, 60, 61, 62, 63]. 
After  this  cleavage,  the  cysteine  residue  is  modified  by  methylation  [64,  65,  61]. 
Isoprenylation and methylation of the COOH-terminal cysteine residues are both necessary 
for the localization of lamin A and the B-type lamins to the INM. Once at the INM A- and B- 
type lamins have different fates: while B-lamins are completely processed and thanks to its 
stable C-terminal farnesylation associates tighly to the INM , A-lamins are further cleaved at 
the C-terminus, losing the last 18 residues.  
Another  fundamental  modification  is  phosphorylation  as  lamins  undergo  dynamic 
rearrangements during interphase and mitosis. Lamins  contain several  target sequence for 
protein kinases, such as cyclin-dependent kinase 1 (cdk1) [66, 67] and nuclear protein kinases 
(PKC)  [68],  whose  phophorylation  mediates  destabilization  and  disassembly  of  lamin 
filaments.  Recruitment  of  protei  phosphatase  1  (PP1)  to  the  INM  is  essential  for  lamina 
assembly at the end of mitosis [69]. 
It  had  traditionally  been  thought  that  the  nuclear  lamina  functions  primarily  to  provide 
structural support and organization to the nuclear envelope. As major structural components 
of  INM,  lamins  have  indeed  a  crucial  role  in  maintaining  the  architecture  of  the  NE, 
anchoring  and  guiding  the  positioning  of  NCPs  via  nucleoporin  Nup153  [70,  71]  and 
supporting other nuclear envelope proteins, but several reports have documented that lamins 
have multiple and disparate roles (Broers J. L. V., F. C. S. Ramaekers, G. Bonne, R. Ben 
Yaou and C. J. Hutchison. Nuclear lamins: laminopathies and their role in premature ageing. 
Physiol  Rev  86:967-1008,  2006.;      H.J.  Worman1,  J.-C.  Courvalin2  The  Inner  Nuclear 
Membrane. J. Membrane Biol. 177, 1–11 (2000) ): they are also important to organize cellular 
cytoskeleton,  binding  to  actin  ,  intermediate  filaments  [46,  72]  and  in  C.Elegans  and 
Drosophila  also  to  microtubules  [73,  74];  they  are  critical  for  DNA  replication  and,  in 
particular, lamin B seems to participate directly to DNA synthesis, even if contrasting data 
have reported an involvement at the stage of initiation [75, 76, 77]; finally both types of   12
lamins have functions in transcription regulation, as B-type are involved in the basic process 
of RNA synthesis, binding RNA polymerase II, while A-type lamins binds and influence the 
activity of transcription regulator proteins, such as SREBP1[78], MOK2 [79], c-Fos [80] and 
Rb [81] . 
In conclusion, nuclear lamina is an essential and multitask cellular structure which interacts 
with several cellular proteins both in the nucleus and in the cytoplasm.  
In this contest, it comes obvious that nuclear lamina cannot avoid to be involved in the deep 
cellular re-arrangements that viruses cause during their replicative cycle.  
The effects of viral infections on nuclear architecture have been reported in several studies 
and different viruses are shown to affect both nuclear functions [82](DNA transcription and 
synthesis) and structure (lamins and NET proteins)[83, 84, 85]. 
In the last years, nuclear envelope re-arrangements due to viral infection has become a hot 
topic especially concerning herpesviruses. 
Herpesviruses  capsid  ,  in  fact,  assembly  and  acquire  their  genome  inside  the  nuclear 
compartment, but all the final events of maturation occur in the cytosol of the host cell[29]. In 
this  contest,  the  stage  of  viral  egress  from  the  nucleus  to  the  cytoplasm  acquires  a 
fundamental importance for the virus replicative cycle and the major obstacle opposing to this 
event  is  essentially  the  thick  protein  meshwork  that  underlines  the  nuclear  envelope 
membrane: the nuclear lamina[86, 87, 31]. 
Herpesviruses seem to have elaborated a fine strategy to dismantle this “cellular barrier”: 
evidences have demostrated lamina components appear deeply affected during infection and 
that both viral and cellular factors (but virally induced) are involved in causing the alterations. 
The most studied herpesviruses in relation to these events belong to the α-subfamily, whose 
main  representatives  are  Herpes  Simplex  type  1  and    type  2  (HSV-1;  HSV-2)  and 
Pseudorabies Virus (PrV), but evidences are reported also concerning β- and γ-subfamily of 
herpesviruses (HCMV and Murine CMV and Epstein-Barr Virus (EBV), respectively). 
As regards HSV-1, several reports indicate  both lamin B and A/C show perforations  and 
distortions  at  the  nuclear  rim  and  a  partial  dislocation  into  the  cytoplasm  [84,  88,  89]. 
Concerning levels of expession during infection, contrasting data have been reported: some 
studies describe an increase of the solubility and a reduction of the total amount of  lamins, 
due to a uniform thinning or in discrete foci, in order to let the capsids reach the nuclear 
membrane easily [89], while others report only in some cell lines this happens and in a limited 
degree, as nuclear lamina is important for cellular functions and the virus, relying on the host 
cell machinery for its replication, affects nuclear lamina, but, at the same time, limits the   13
disruption,  to  take  advantage  [90].  Recently,  a  recruitment  of  atypical  Protein  Kinases  C 
(PKC) at the nuclear rim has been reported during HSV-1 infection, resulting in lamin B 
phosphorylation[91]. Moreover, also emerin has been found modified, as new phosphorylated 
forms  of  this  nuclear  transmembrane  protein  have  been  discovered  in  infected  cells  [84]. 
Similar results emerged from the analysis of cells infected by EBV, a γ-herpesvirus. 
Lamins appears to be affected also during CMV infection. In the past, analysis of lysates of 
HCMV infected samples indicated the quality of the phsphorylation of lamin A/C is altered: 
using a monoclonal antibody versus a specific phosphorylated epitope of lamin A/C, located 
within the first 417 aminoacids, data showed a rearrangement of the phosphorylation in lamin 
A/C and a decrease in that specific site [34]. More recently, it has been reported that Murine 
Cytomegalovirus  is  responsible  of  a  recruitment  of  PKCs  at  the  nuclear  rim  and  during 
infection, both B-type and A-type lamins show an increase of the phosphorylation levels, 
suggesting a their dissolution [87]. Moreover, it has been reported that an increase of HCMV 
molteplicity of infection causes a reduction of total amount of lamin A/C [92].  
More  similar  data  among  the  different  Herpesviridae  subfamilies  have  been  reported  by 
electon  microscopy  observations:  invaginations  and  large  infoldings  of  nuclear  envelope 
appears evident during infection, suggesting an increase of membrane surface to facilitate 
viral egress[83, 93, 94, 86, 95, 96]. 
In conclusion, lamina is a nuclear component, fundamental for both structural maintenance 
and several functional activities essential for cellular life cycle. After infection, a virus has to 
manage this enourmous barrier to its replication and maturation, mainly operating alterations 
of nuclear envelope membranes and protein components, but with contained effects, in order 
to maintain those nuclear essential functions, which important also for the production of viral 
progeny. 
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1.3 VIRAL EGRESS FROM THE NUCLEUS: HERPES SIMPLEX TYPE 1 PUL31 AND  
PUL34 AND THEIR HOMOLOGS. 
 
During herpesvirus infection, viral transcription, DNA replication, formation of capsids, and 
packaging of viral DNA occur in the nucleus [30, 97, 98]. Subsequently, intranuclear capsids 
have to leave the nucleus to gain access to the cytoplasmic environment, that represents the 
final site of maturation for viral particles. In this contest, nuclear envelope and, in particular, 
nuclear  lamina  provides  the  major  obstacle  to  movement  of  herpesvirus  virions  into  the 
cytoplasm.  
This  process  has  been  studied  in  depth  in  particular  in  α-herpesviruses,  such  as  Herpes 
Simplex  type  1  (HSV-1)  and,  among  the  different  models  proposed,  several  observations 
strongly  support  the  envelopment  -  de-envelopment  –  re-envelopment  model:  in  order  to 
achieve the cytoplasmic compartment, viral particles bud through the inner nuclear membrane 
(INM), reaching the perinuclear space; then the viral primary envelope fuses with the outer 
leaflet of the nuclear membrane, resulting in the release of un-enveloped and presumably 
untegumented capsids into the cytoplasm, where final tegumentation and envelopment occur, 
budding through trans-Golgi vesicles. 
Electron microscopic analyses indeed demonstrated the validity of this model, as highlighted 
differences  between  primary  virions  and  mature  extracellular  ones  in  morphology,  in 
tegument composition and in biochemical composition of the envelope [94], indicating that 
the primary envelope has to be lost and replaced by another one originated from extranuclear 
membranes of the host cell. Moreover electron microscopy evidences reported the presence of 
enveloped  viral  particles  in  the  perinuclear  space  and  in  the  area  adjacent  to  trans-Golgi 
apparatus, while virions localized inside the nucleus and in the cytoplasmic compartment 
nearby the ONM lacked of envelope [94, 99, 96].  
Nucleocapsids of primary virions are translocated into the cytosol after fusion of the primary 
envelope with the outer leaflet of the nuclear membrane (Stackpole, 1969; Severi et al., 1979; 
Smith, 1980). The molecular mechanism of this fusion process is unknown but two virally 
encoded proteins have been shown to be crucial. These are the products of the UL31 and 
UL34 genes of herpes simplex virus 1[100, 101] and homologous proteins of PrV ([102, 103] 
and MCMV [87]. Interestingly, homologs of these proteins are present in members of all three 
herpesvirus  subfamilies,  including  varicella-zoster  virus[104],  human  cytomegalovirus 
(HCMV)  [53],  human  herpesvirus-  6  [105],  human  herpesvirus-7  [106]  and  Epstein±Barr   15
virus  [30],  indicating  that  their  function  may  be  conserved  throughout  the  Herpesviridae 
family [30, 53, 107]. 
UL34  protein  represents  a  type  II  membrane  proteins  with  a  C-terminal  transmembrane 
domain  but  without  a  signal  sequence  [108,  107,  109,  110],  which  is  either  directly  or 
indirectly phosphorylated by the HSV protein kinase US3 [40, 111, 109, 112] UL34 protein is 
a late gene product and is found to be a component of HSV-2 virions.  In transfected cells,the 
protein  is  clustered  strongly  in  the  perinuclear  region  and  also  detected  dispersed  in  the 
cytoplasm [103, 87, 113, 110].  
The UL31 gene product is a phosphorylated protein, detectable at late times post-infection, 
that is able to interact with that nuclear matrix[114]. When singularly expressed, localizes into 
the nuclear compartment thanks to a nuclear localization signal (NLS) at its N-terminus, but 
does not become associated with the nuclear membrane. 
In cells infected with either HSV-1, PrV or MCMV, both pUL34 and pUL31 are concentrated 
in the nuclear membrane, indicating that they need other viral protein(s) for their distinct 
perinuclear  localization: it has indeed been shown that when co-expressed the UL34 proteins 
physically interact with the respective gene products of the UL31 genes (Bjerke et al., 2003; 
Fuchs  et  al.,  2002a;  Muranyi  et  al.,  2002;  Reynolds  et  al.,  2001)and  this  interaction  is 
sufficient for their re-localization at the nuclear rim [115, 102, 87, 116, 117] 
Thus, complex formation between the UL31 and UL34 proteins apparently is required for 
efficient transport of the UL34 protein into or retention in the nuclear compartment by UL31, 
and for nuclear membrane localization of UL31 by interaction with UL34, that inserts into the 
INM and functions as an anchorage for UL31. The domains responsible of the interaction are 
different in different herpesviruses: in HSV-1 pUL34 the binding region to pUL31 is located 
in the centre of the sequence[118], while in M50, the homolog in MCMV, resides at the N-
terminus[119]. However, it has been demonstrated that even if the positions of the binding 
domain are different, homolog  proteins are able to complement each other in interact with 
pUL31 and homologs, indicating the function is conservated. In contrast, as regards pUL31, 
the  variability  seems  to  be  higher,  as  complementation  assays  among  the  homologs 
failed[120]. 
In the absence of either protein, primary envelopment is inhibited and capsids accumulate in 
the  nucleus  as  shown  for  respective  deletion  mutants  of  HSV-1,  reducing  viral  titers  by 
several log. These data suggest their function is very important, though not strictly essential 
for formation of infectious virions [100, 102, 103, 101].   16
The UL31 and UL34 gene products have been shown to be constituents of primary enveloped 
virions but not mature virus particles [102, 108, 121], whereas other tegument and envelope 
proteins present in mature virions have not been detected in primary virus particles[122]. 
Only one virally encoded protein, the product of the US3 genes of PrV and HSV-1, has been 
identified which plays a role in this fusion process. US3 homologous proteins are present only 
in  the  alphaherpesviruses  and  they  represent  protein  kinases  [123,  98].  Strikingly,  in  the 
absence  of  US3,  primary  virions  accumulate  in  the  perinuclear  space  [124,  121,  125]. 
Apparently,  primary  envelopment  occurs  in  the  absence  of  the  US3  protein,  but  de-
envelopment is impaired: deletion of the US3 gene reduces infectivity only about 10-fold, 
indicating  that  the  US3  function  in  nuclear  egress  is  beneficial  but  not  essential.  This 
correlates with the fact  that US3, in contrast to UL31  and UL34, is not conserved in all 
herpesvirus subfamilies. The UL34 protein of HSV-1 has been proposed as a substrate for the 
US3 kinase, which could indicate that the role of US3 in nuclear egress may be indirect by 
modulating UL34 activity via phosphorylation [112]. However, in PrV the UL34 protein is 
not phosphorylated, at least not exclusively, by the US3 kinase [124], although localization of 
UL34, and consequently of pUL31, in the nuclear membrane is influenced by the presence of 
the US3 protein [124, 121]: in the absence of US3, in fact, UL31 and UL34 still co-localize but 
loose their smooth and homogeneous distribution, localizing within punctate aggregates that 
accumulate predominantly at the nuclear rim [121]. 
As previously reported, HSV has been shown to alter nuclear architecture [126], inducing 
perforations and distortions and to increase nuclear lamina phosphorylation and disassembly 
by recruiting cellular PKC at the nuclear rim.  
pUL31 and pUL34 are reported to be essential for nuclear lamins modifications occurring 
during infection, as recombinant viruses deleted for either pUL31 or pUL34 maintain integral 
the nuclear envelope and its components [127] and, in this way, do not enable nuclear capsids 
to access the INM (HSV-1 [100, 101] and PrV [102, 103] ).   
In MCMV, it has been shown UL34 homolog is responsible of cellular PKC recruitment, 
playing a role in the phosphorylation of nuclear lamins [87]. Moreover, the two viral proteins 
seem  to  interact  with  lamin  A/C  in  vitro  [88]  and  the  homologs  in  EBV  are  able  to  co-
immunoprecipitate with lamin B [93]. Anyway, most of data reported support the hypothesis 
that pUL31 and pUL34 are necessary to affect lamins but do not act directly[88]. 
Recently, a protein kinase pUL97 of HCMV has been reported to be partially involved in 
lamina  dissolution,  as  its  over-expression  induces  a  decrease  of  total  amount  of  lamin 
A/C[92], even if infection with a recombinant virus deleted for UL97 showed the viral protein   17
kinase is not essential for HCMV replication and lamins still appear alterated . A synergic 
action of pUL97 and pUL31 and pUL34 homologs has been proposed, as HCMV pUL31 
homolog, called pUL53, has been found to co-localize with lamin A/C and lamin B [128]. 
Finally, all these reports describe UL31 and UL34 products and their homologs like viral 
factors essential for nuclear capsid egress and, in particular, for primary envelopment: their 
action at the nuclear rim is necessary to induce those nuclear lamina modifications that allow 
virions to reach the INM and begin the budding events that will lead them to maturation. 
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1.4 RNA INTERFERENCE: A POTENT TOOL FOR GENE SILENCING 
 
Post-transcriptional  gene  silencing  (PTGS)  was  initially  considered  a  rare  phenomenon 
limited to few plant species but in the last years, it has become clear that PTGS occurs in both 
plants and animals and has roles in viral defense and transposon silencing mechanisms. PTGS 
and, in particular, RNA interference (RNAi) — PTGS initiated by the introduction of double-
stranded RNA (dsRNA) — are considered a tool to knock out expression of specific genes in 
a variety of organisms [129, 130, 131]. Although transgene-induced silencing in some plants 
appears  to  involve  gene-specific  methylation  (transcriptional  gene  silencing,  or  TGS),  in 
others silencing occurs at the post-transcriptional level (post-transcriptional gene silencing, or 
PTGS): the homologous transcript is made, but that it is rapidly degraded in the cytoplasm 
and does not accumulate [129, 131, 132] Both biochemical and genetic approaches have led 
to the current models of the RNAi mechanism.that consists of an initiation and an effector 
step [131, 133]. In the initiation step, input dsRNA is digested into 21-23 nucleotide small 
interfering  RNAs  (siRNAs),  which  have  also  been  called  "guide  RNAs"  [133,  134]. 
Evidences indicate that siRNAs are produced when the enzyme Dicer, a member of the RNase 
III family of dsRNA-specific ribonucleases, processively cleaves dsRNA (introduced directly 
or via a transgene or virus) in an ATP-dependent processive manner. Successive cleavage 
events degrade the RNA to 19-21 bp duplexes (siRNAs), each with 2-nucleotide 3' overhangs 
[135, 133]. In the effector step, the siRNA duplexes bind to a nuclease complex to form what 
is  known  as  the  RNA-induced  silencing  complex,  called  RISC.  An  ATP-depending 
unwinding of the siRNA duplex is required for activation of the RISC. The active RISC then 
targets the homologous transcript by base pairing interactions and cleaves the mRNA ~12 
nucleotides  from  the  3'  terminus  of  the  siRNA  [131,  134].  Although  the  mechanism  of 
cleavage is not completely clear, evidences indicate that each RISC contains a single siRNA 
and  an  RNase,  called  Slicer,  that  appears  to  be  distinct  from  Dicer[133].  Because  of  the 
remarkable  potency  of  RNAi  in  some  organisms,  an  amplification  step  within  the  RNAi 
pathway has also been proposed. Amplification could occur by copying of the input dsRNAs, 
which  would  generate  more  siRNAs,  or  by  replication  of  the  siRNAs  themselves. 
Alternatively or in addition, amplification could be effected by multiple turnover events of the 
RISC [131, 133, 134]. 
While the natural presence of RNAi had been observed in a variety of organisms (plants, 
protozoa, insects, and nematodes), evidence for the existence of RNAi in mammalian cells   19
took  longer  to  establish.  Transfection  of  long  dsRNA  molecules  (>30  nt)  into  most 
mammalian cells causes nonspecific suppression of gene expression, as opposed to the gene-
specific  suppression  seen  in  other  organisms.  This  suppression  has  been  attributed  to  an 
antiviral response, which takes place through one of two pathways. In one pathway, long 
dsRNAs  activate  a  protein  kinase,  PKR,  that  in  turn  phoshorylates  and  inactivates  the 
translation  initiation  factor,  eIF2a,  leading  to  repression  of  translation  [136].  In  the  other 
pathway, long dsRNAs activate RNase L, which leads to nonspecific RNA degradation [137]. 
Interestingly, dsRNAs less than 30 nt in length do not activate the PKR kinase pathway. This 
observation, as well as knowledge that long dsRNAs are cleaved to form siRNAs in worms 
and flies, prompted researchers to test whether introduction of siRNAs could induce gene-
specific  silencing  in  mammalian  cells  [138].  Indeed,  siRNAs  introduced  by  transient 
transfection  were  found  to  effectively  induce  RNAi  in  mammalian  cultured  cells  in  a 
sequence-specific manner. The effectiveness of siRNAs varies — the most potent siRNAs 
result in >90% reduction in target RNA and protein levels [139, 48, 140]. The most effective 
siRNAs turn out to be 21 nt dsRNAs with 2 nt 3' overhangs. Sequence specificity of siRNA is 
very  stringent,  as  single  base  pair  mismatches  between  the  siRNA  and  its  target  mRNA 
dramatically  reduce  silencing  [48,  141].  Unfortunately,  not  all  siRNAs  with  these 
characteristics are effective. The reasons for this are unclear but may be a result of positional 
effects  [140]  Jarvis  RA,  and  Ford  LP.  (2001)  The  siRNA  Target  Site  Is  an  Important 
Parameter for  Inducing RNAi in Human Cells. TechNotes 8(5): 3-5., Brown D, Jarvis R, 
Pallotta V, Byrom M, and Ford L. (2002) RNA Interference in Mammalian Cell Culture: 
Design,  Execution  and  Analysis  of  the  siRNA  Effect.  TechNotes  9(1):  3-5.).  In  early 
experiments with mammalian cells, the siRNAs were synthesized chemically. So far, injection 
and transfection of dsRNA into cells and organisms have been the main method of delivery of 
siRNA. And while the silencing effect lasts for several days and does appear to be transferred 
to daughter cells, it does eventually diminish. Recently, however, a number of groups have 
developed  expression  vectors  to  continually  express  siRNAs  in  transiently  and  stably 
transfected mammalian cells [142, 143, 144, 145, 146, 147, 148] As recent findings in C. 
elegans, Drosophila, plants and Trypanosomes demonstrate RNAi can be induced by an RNA 
molecule  that  folds  into  a  stem-loop  structure  [131],  some  of  these  vectors  have  been 
engineered  to  express  small  hairpin  RNAs  (shRNAs),  which  get  processed  in  vivo  into 
siRNAs-like molecules capable of carrying out gene-specific silencing [142, 145, 148].  
In the last years, RNAi is acquiring importance as it is considered a potential effective tool, 
with also anti-viral therapeutic potentials. Several studies, concerning a variety of viruses,   20
have  shown  RNA  interference  has  given  good  result  inhibiting  viral  replication,  using  as 
targets  the  transcripts  of  essential  viral  genes.  A  part  from  this  potential  and  important 
application,  RNA  interference  remains  a  useful    instrument  for  basic  research,  as  post-
transcriptional silencing allows to modify the pattern of gene expression without manipulating 
genic sequences, an important advantage, in particular, to silence genes that are inverted on 
the genome sequences and share nucleotides with adjacent open reading frames. 
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2. MATHERIALS AND METHODS 
 
   
 
 
 
2.1 Cell culture and viruses. 
Primary human lung fibroblasts (HELFs) were cultivated in MEM, containing 10% foetal 
bovine serum; COS7 cells in DMEM containing 5 % foetal bovine serum. HCMV laboratory 
strain AD169 was propagated in HELFs. Infections were performed at a MOI of 0,5 as briefly 
described: cells 
were washed once with MEM without serum and inoculated with the appropriate dilution of 
viral stock; after an incubation of 1h at 37°C in gentle agitation, the inoculum was removed 
and replaced with fresh MEM containing 10% foetal bovine serum. 
 
2.2 Plasmids encoding pUL53 and pUL50. 
Plasmid  pc53FLAG  has  been  previously  described  (Dal  Monte  et  al.,  2002).  To  express 
pUL53 as a fusion protein with 6XHis tag in bacteria, UL53 ORF has been cloned in pCR 
T7/CT-TOPO (Invitrogen, Carlsbad, CA, USA). UL53 ORF has been amplified by PCR using 
the upper primer UL53-U21 and the lower UL53-L21 (see Table 2.1), lacking of the STOP 
codon, contained in the vector,  downstream the sequences encoding 6XHis and V5 epitopes. 
The PCR product has been incubated with the linearized vector for 5 min at room temperature 
and the resulting plasmid, pCR TOPO-UL53, was used to transform the bacterial strain E.Coli 
BL21(DE) for bacterial expression and JM109 for plasmid propagation.             
UL50 ORF was amplified by PCR from HCMV strain AD169 genome using the primers 
UL50-U18    and  UL50-L16  (see  Table  2.1).  The  PCR  product  has  been  inserted  in  pCR 
T7/CT-TOPO,  originating  the  plasmid  pCR  TOPO-UL50.  To  obtain  the  eukaryotic 
expression vector pcDNA-UL50V5,  pCR TOPO-UL50  was cut with the restriction enzymes   22
XbaI and PmeI and the resulting sequence, containing UL50 ORF in frame with 6XHis and 
V5 epitopes, was subcloned in the EcoRV site of pcDNA3 plasmid (Invitrogen, Carlsbad, 
CA, USA). 
 
 
2.3 Expression and purification of pUL53-6XHIS fusion protein.  
The construct pCR T7 TOPO-UL53 described above was used to chemically transform the 
Escherichia Coli  BL21(DE) strain, a bacterial strain optimized for protein expression. For 
production of pUL53-6XHIS, 10 ml of fresh stationary-phase culture was inoculated into 500 
ml of Luria broth (LB) supplemented with ampicillin (50 µg/ml). The bacterial culture was 
grown at 37°C until an optical density at 600 of nm 0.6 and protein expression was induced 
with 5 mM isopropylthiogalactopyranoside (IPTG) for 6 h at 28°C, in gentle shaking. The 
protein was purified by affinity chromatography using the Invitrogen ProBond Purification 
System  for  6XHis  tagged  proteins  (Invitrogen,  Carlsbad,  CA,  USA),  according  to 
manifacturer’s instructions. Briefly, the bacterial pellet was lysed in denaturing conditions 
with  Guanidinium  Lysis  Buffer  (6  M  Guanidine  Hydrochloride;  500  mM  NaCl;  20  mM 
Sodium Phosphate, pH 7.8) and sonicated 3 times with 10 sec pulses at medium intensity with 
sonicator  Bandelin  Sonoplus  (Bandelin  Electronic,  Berlin,  Germany).  After  a  30  min 
centrifugation  at  3000xg,  the  supernatant  was  harvested,  loaded  on  purification  columns, 
previously washed with water and equilibrated with Denaturing Binding Buffer (8 M Urea; 
500 mM NaCl; 20 mM Sodium Phosphate pH 7.8), and incubated at room temperature for 30 
min in gentle agitation. After two washes with Denaturing Binding Buffer and Denaturing 
Wash  Buffer  (8  M  Urea;  500  mM  NaCl;  20  mM  Sodium  Phosphate,  pH  6  and  pH  5.3 
respectively), pUL536XHis was eluted using Denaturing Elution Buffer (8 M Urea; 500 mM 
NaCl; 20 mM Sodium Phosphate; pH 4.0). 
 
2.4 Production of anti-pUL53 antibody.  
 The pUL53 affinity purified protein was denatured in SDS and separated by electrophoresis 
on  10%  denaturing  polyacrylamide  gels,  stained  with  Coomassie  blue  or  transferred  on 
nitrocellulose membrane and revealed for the expression of  V5 epitope. As Western Blot 
analysis revealed two specific bands with molecular weight of about 40 KDa and 28 kDa, the 
most abundant was chosen to obtain the antibody. The purified protein was separated on 9% 
denaturing polyacrylamide gel, stained with CaCl2, cut out of the gel and electroeluted. After 
a  step  in  PD-10  Desalting  Columns  (Amersham  Biosciences,  Buckinghamshire,  UK),  the 
recombinant protein has been concentrated by evaporation at 4° C, using  UniVapo 150H   23
(UniEquip,  Martinsried,  Germany),  to  the  final  concentration  of  a  final  concentration 
0.45µg/µl and used to immunize laboratory mice.  
To produce the polyclonal anti-serum anti-pUL53, six BALB\c mice have been immunized 
with the purified protein and three with water as negative control. The immunogen (45µg in 
100µl of water) an the negative control were emulsioned with an excess of complete Freund’s 
adjuvant  and  injected  once  a  week,  for  six  weeks  into  the  intraperitoneal  cavity  of  the 
BALB\c mice (Cevenini et al., 1991). The ascytes containing the polyclonal antibody against 
pUL53 and the controls were prelevated and tested to evaluate the specificity by Western Blot 
on lysates of mock and pc53Flag-transfected COS7 cells. 
 
2.5 Plasmids encoding GFP fusion proteins (Gateway Technology®).  
Every construct expressing fusion proteins between pUL53 or pUL50 fragments and GFP or 
DsRed was generated using Gateway Technology® (Invitrogen, Carlsbad, CA, USA) (see 
paragraph  2.6  The  gateway  Technology).  The  sequences  were  amplified  by  PCR  with 
AmpliTaq  Gold  polymerase  (Roche,  Branchburg,  New  Jersey,  USA),  using  appropriate 
primers containing AttB1 and AttB2 sites (listed in Table 2.1) and the plasmids pcDNA50V5 
and  pc53Flag  as  templates.  After  electrophoretic  separation  in  1%  agarose  gel,  PCR 
fragments were purified using the commercial extraction kit Cleanmix (Talent, Trieste, Italy), 
according  to  manifacturer’s  instructions,  and  cloned  in  the  donor  vector  pDONOR207 
(Invitrogen, Carlsbad, CA, USA) by BP reaction, obtaining the entry clones listed in Table 
2.2. All entry clones were sequenced by PRIMM Srl (PRIMM Srl, Milan, Italy). To obtain 
expression clones (see Table 2.2), LR reactions were performed using pDONOR vectors and 
the  destination  vectors  pDEST53  (Invitrogen,  Carlsbad,  CA,  USA)  and  pBKdsRed2CMV 
(Soboleva  et  al.,  Nuclear-cytoplasmic  shuttling  of  the  oncogenic  mouse  UNP/USP4 
deubiquitylating enzyme. J Biol Chem, 2005. 280(1): 382-52). The integrity of expression 
vectors was verified by enzymatic digestion with appropriate restriction enzymes. 
 
2.6 The Gateway Technology. 
The Gateway® Technology is based on the bacteriophage lambda site-specific recombination 
system which facilitates the integration of lambda into the E. coli chromosome and the switch 
between  the  lytic  and  lysogenic  pathways:  the  components  of  the  lambda  recombination 
system are modified to allow an intermolecular DNA recombination that is mediated by a 
mixture of lambda and E. coli-encoded recombination proteins.   24
Lambda recombination occurs between site-specific attachment (att) sites, attB on the E. coli 
chromosome  and  attP  on  the  lambda  chromosome,  which  represent  the  binding  site  for 
recombination proteins. Upon lambda integration, recombination occurs between attB and 
attP sites to give rise to attL and attR sites. The actual crossover occurs between homologous 
15 bp core regions on the two sites, but surrounding sequences are required as they contain 
the binding sites for the recombination proteins. 
Lambda recombination is catalyzed by a mixture of enzymes that bind to specific sequences 
(att  sites),  bring  together  the  target  sites,  cleave  them,  and  covalently  attach  the  DNA. 
Recombination occurs following two pairs of strand exchanges and ligation of the DNAs in a 
novel  form.  The  recombination  proteins  involved  in  the  reaction  differ  depending  upon 
whether lambda utilizes the lytic or lysogenic pathway The lysogenic pathway is catalyzed by 
the  bacteriophage  λ  Integrase  (Int)  and  E.  coli  Integration  Host  Factor  (IHF)  proteins 
(included  in  BP  Clonase™  enzyme  mix)  while  the  lytic  pathway  is  catalyzed  by  the 
bacteriophage λ Int and Excisionase (Xis) proteins, and the E. coli Integration Host Factor 
(IHF) protein (included in LR Clonase™ enzyme mix) (Fig. 2.1). 
The Gateway® Technology uses the lambda recombination system to facilitate transfer of 
heterologous DNA sequences (flanked by modified Att sites) from an entry vector to a variety 
of destination vectors, generating specific expression clones (Fig. 2.2). Two recombination 
reactions constitute the basis of the Gateway® Technology: 
−  BP Reaction: facilitates recombination of an attB substrate (attB-PCR product or a 
linearized attB expression clone) with an attP substrate (donor vector) to create an attL-
containing entry clone (Fig. 2.3). This reaction is catalyzed by BP Clonase™ enzyme 
mix. 
−  LR Reaction: facilitates recombination of an attL substrate (entry clone) with an attR 
substrate (destination vector) to create an attB-containing expression clone (Fig. 2.4). 
This reaction is catalyzed by LR Clonase™ enzyme mix. 
 
2.7 Transfection. 
Transient transfection of subconfluent COS7 cells and HELFs was performed at a confluency 
of 75 %, using  Lipofectamine2000 (Invitrogen, Carlsbad, CA, USA) or Fugene6 (Roche) 
according to the manufacturers’ instructions. Transfected cells were fixed or harvested after 
24-48  hours  after  transfection  and  analized  by  Immunofluorescence  assay  and 
ImmunoBlotting assay.   25
2.8 Immunofluorescence assay. 
 96-120 h post-infection or 48h post-transfection, cells were fixed in 4% formaldehyde in PBS 
for 10 min at 4°C and permeabilized with methanol at  -20°C for 10 min. After 3 washes in 
PBS, cells were blocked with BSA 4% in PBS for 30 min and then incubated for 1 hour at 
37°C  with  the  following  primary  antibodies:  mouse  monoclonal  anti–Flag  M2  (Sigma-
Aldrich, St. Louis, MO, USA) dilution 1:250; mouse monoclonal anti-V5 epitope (Invitrogen, 
Carlsbad, CA, USA) 1:500; mouse polyclonal anti-pUL53 1:100; goat polyclonal anti-lamin 
A/C (S. Cruz Biotechnology, Santa Cruz, CA, USA) 1:10; goat polyclonal anti-lamin B (S. 
Cruz  Biotechnology,  Santa  Cruz,  CA,  USA)  1:10;  mouse  monoclonal  IgM  SW2-30  pure 
(kindly provided by Professor Radsak, Marburg, Germany);  mouse monoclonal IgG anti-gB 
pure (kindly provided by Professor Mach, Erlangen, Germany); mouse monoclonal IgM 14-
16 anti-gN pure (kindly provided by Professor Mach, Erlangen, Germany). After 3 washes 
with PBS, cells were incubated for 1 hour at room temperature with fluorochrome conjugated 
secondary antibodies Alexa Fluor (Invitrogen, Carlsbad, CA, USA) diluted 1:1000 in PBS. 
Chromatin staining was performed using DAPI (4’6’-diamidino 2-phenylindole) diluted 0,1 
ng/ml for 3 min at room temperature. After 3  washes, the coverslips were mounted with 
Polyvinyl Alcohol Mounting Media with DABCO (Sigma-Aldrich, St. Louis, MO, USA) and 
analyzed with a fluorescence microscope Nikon Eclipse 600 (Nikon, Enfield, CT, USA) with 
a 100X oil objective. The images were acquired using Lucia Image software. 
 
2.9 Leptomycin B treatment and Confocal laser microscopy on living cells. 
The subcellular localization of the fusion proteins with GFP has been analized in living cells 
24 h post- transfection and after 4 h of treatment with Leptomycin B (LMB) with a final 
concentration of 4ng/ml by  confocal laser scanning microscopy (CLSM) using a Bio-Rad 
MRC  600  system  with  a  fluorescence  microscope  Nikon  and  a  40X  objective.  The  ratio 
between nuclear and cytoplasmic fluorescence for every fusion protein has been calculated as 
previuosly,  using  Image  J  1.6  software  (National  Institute  of  Health,  USA)  and  the 
mathematical formula Fn/c=(Fn-Fb)/(Fc-Fb), where F stands for fluorescence, n for nuclear, 
c for cytoplasmic and b for background.. 
 
2.10 Sub-cellular fractioning. 
Sub-cellular fractioning  of mock-infected  and infected  HELFS  was performed to separate 
cytoplasmic and nuclear proteins. Cells were resuspended lysis buffer containing 10 mM Tris-
HCl pH 7.8, 1% Nonidet P-40 (NP-40), 10 mM 2-mercaptoethanol and protease inhibitors.   26
The separation was achieved by hypotonic shock and shearing; nuclei were obtained as pellet 
by a 300xg centrifugation at 4°C and the supernatant representing the cytoplasmic fraction 
was clarified by centrifugation at 600xg. Pellets containing purified nuclei were resuspended 
in  RIPA  buffer  (10mM  Tris-HCl;  150mM  NaCl;  1mM  EDTA;  0.1%  SDS;  0.5%  sodium 
deoxycolate; 1% TritonX-100; 1mM Na3VO4; 1mM PMSF), sonicated at low intensity for 15 
sec  and  cleared  from  nuclear  debris  by  a  14000  rpm  centrifugation  at  4°C  for  10  min. 
Cytoplasmic and nuclear samples were additioned with Laemmli’s sample buffer and loaded 
on 5-20% gradient polyacrylamide gels.  
 
 
2.11 Immunoprecipitation. 
To  perform  immunoprecipitation  assay,  COS7  cells  were  harvested  48h  post-transfection, 
while infected and mock-infected HELFs 96-120 h post-infection. Cells were washed twice 
with phosphate-buffered saline (PBS) and lysed in Triton-X lysis buffer (50 mM Tris-HCl 
[pH 7.4], 150 mM NaCl, 1% Triton-X , protease inhibitor cocktail [Roche]) for 10 min in ice 
and sonicated at low intensity for 10 seconds. After 20 min of centrifugation at 14000 rpm, 
the supernatants were collected and mixed with the appropriate antibody (4 µg/sample) and 
incubated overnight at 4°C while rocking gently. The day after, 30µl of protein A/G-beads (S. 
Cruz Biotechnology) were added and incubated at 4°C while rocking gently. After 4h, the 
beads were collected b centrifugation for 1 min at 1000 rpm and washed three times with 
Triton-X Lysis buffer for 15 min at 4°C while rocking gently. After the last washing, the 
beads were resuspended in Laemmli’s buffer 2X, boiled at 95°C and centrifugated at 14000 
rpm for 5 min, before loading the supernatant on 8% or 10% SDS-PAGE gel. 
 
2.12 Western blotting. 
 After  SDS-PAGE  electophoresis,  proteins  were  transferred  on  PROTRAN  Nitrocellulose 
Transfer Membrane (Schleischer & Schuell Biosciences, Dassel, Germany). The membranes 
were blocked with non fat milk (Bio-Rad, Hercules, CA, USA) 5% in PBS-0,1% Tween20, 
washed  three  times  with  PBS-0,1%  Tween  20  and  probed  with  the  following  antibodies: 
mouse monoclonal anti-Flag (Sigma-Aldrich, St. Louis, MO, USA), mouse monoclonal anti-
V5 mouse (Invitrogen, Carlsbad, CA, USA ); polyclonal anti-pUL53, dilution 1:150; goat 
polyclonal  anti-lamin  A/C  (S.  Cruz  Biotechnology,  Santa  Cruz,  CA,  USA),  1:100;  goat 
polyclonal anti-lamin B (S. Cruz Biotechnology, Santa Cruz, CA, USA), 1:100. After washes 
with  PBS-0,1%  Tween20,  the  membranes  were  incubated  with  secondary  antibodies   27
conjugated  to  horseradish  peroxidase  (DAKO,  Glostrup,  Germany),  diluted  1:10,000  and 
washed again 3 times. The signal was detected with enhanced chemiluminescence reagents 
(ECL,  Amersham  Biosciences,  Buckinghamshire,  UK)  on  standard  X-ray  film  (Kodak, 
Rochester, NY, USA). 
 
2.13 Plasmid for RNA interference against UL53 ORF transcript. 
To  perform  RNA  interference  versus  UL53  transcript  during  infection,  the  plasmid  pG-
SUPER  has  been  used  (Fig.2.1):  the  plasmid  contains  two  human  promoters,  leading  the 
transcription of GFP encoding gene, as marker of transfection, and the transcription of a small 
hairpin RNA directed against UL53 ORF [142, 149]. The gene-specific insert is designed to 
specify  a  19  nucleotide  sequence  derived  from  the  target  transcript,  separated  by  a  short 
spacer  from  the  reverse  complement  of  the  same  19  nucleotide  sequence.  The  resulting 
transcript is predicted to fold back on itself to form a 19-base pair stem-loop structure, that 
will mediate gene silencing. Three specific sequences of 19 nucleotides were individuated on 
UL53  ORF  sequence,  using  a  sequence  design  on-line  software 
(http://bioinfo.clonetech.com/rnaidesigner/sirnaSequenceDesign.do)  and  selected  for  the 
ability  to  not  cross-react  with  other  viral  and  cellular  transcripts,  using  BLAST  software 
(http://www.ncbi.nlm.nih.gov/BLAST). The sequences and the derivating oligonucleotides and 
plasmids are listed in Table 2.3. 
The phosphorylated oligos were chemically synthesized (Geneworks Pty Ltd) and annealed at 
94°C for 4 min, then at 70°C for 10 min and decreasing the temperature 0,1°C/sec until it was 
20°C. Once annealed, the duplexes were inserted in the vector pG-SUPER, digested with the 
restriction enzymes BglII and HindIII (New England Biolabs). After a ligation with T4 Ligase 
(Roche,  Branchburg,  New  Jersey,  USA)  and  bacterial  transformation,  the  colonies  were 
screened by enzimatic digestion and sequencing. 
 
2.14 RNA interference against UL53 ORF transcript. 
To  silence  UL53  ORF  expression  during  viral  infection,  subconfluent  HELFs  have  been 
transfected separately with the plasmids pG-SUPER, as negative control, pG-SUPER-UL53-
224,    pG-SUPER-UL53-757  and  pG-SUPER-UL53-782  encoding  for  GFP,  as  marker  of 
transfection and a small hairpin RNA with interfering properties. The day after, cells have 
been infected with HCMV AD169. 120 h post-infection, cells were fixed and stained for 
pUL53 and gN.  
   28
2.15 Sequence analysis and statistical analysis 
All  sequence  analysis  of  pUL53  and  pUL50  proteins  have  been  performed  manually  and 
using the on-line softwares PSORTII, NetNES and THMM. 
Statistical analysis of data have been performed using the software Sigma Plot 9.0. 
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3. RESULTS 
 
 
 
 
3.1 Nuclear lamina remodelling during HCMV infection  
To determine eventual nuclear alterations occurring during HCMV infection, nuclear lamina 
and, in particular, its major components, lamin A/C and lamin B, were chosen as targets of the 
analysis. The observations were performed on mock- and infected HELFs using commercial 
antibodies directed against lamin B and lamin A/C and a mouse monoclonal antibody reacting 
versus the viral glicoprotein gB, that during infection localizes in the cytoplasmic area, called 
“assembly compartment”. 
In interphasic mock-infected HELFs, nuclei presented a normal ovoid morphology and lamin 
A/C  and lamin B stainings revealed an homogeneous pattern at the nuclear periphery (Fig. 
3.1a - b), with the occasional presence of small dots corresponding to normal invaginations of 
the  nuclear  membrane.  Immunofluorescence  assays  on  infected  fibroblasts  revealed 
remarkable modifications of the nuclear shape and a strong alteration of nuclear lamins. In 
details, while at early stages of infection, no change is detectable, at later stages (72-120 h 
post-infection) lamin B showed a ruffled staining at the nuclear rim with the formation of 
invaginations which increased in number and dimensions during the progression of infection 
(Fig. 3.1a); a similar pattern was observed for lamin A/C (Fig. 3.1b).  
 
 
3.2 Antiserum anti-pUL53 specificity. 
To performe analysis of pUL53 during HCMV infection, a novel antibody directed against the 
viral protein was necessary. Big amounts of protein were obtained inducing the expression of 
pUL53, as a fusion protein with 6XHis epitope, in the bacterial strain E. Coli BL21 (DE), 
transformed with the plasmid pCR TOPO-UL53. The recombinant protein has been purified 
in several steps: as purification by affinity chromatography resulted insufficient, the fractions 
have  been  electrophoretically    separated,  then  the  band  of  interest  has  been  excised  and   30
electroeluted. The purified fraction has been desalted and concentrated to a final concentration 
of  0.45µg/µl and used to immunize laboratory animals. 
The antiserum against pUL53 and the controls have been prelevated and tested for specificity 
by  WB  on  lysates  of  mock-  and  transfected  COS7  cells  with  the  plasmid  pc53Flag  (Dal 
Monte et al, 2002). The antiserum versus pUL53 recognized a specific band in transfected 
fractions,  with  a  specificity  comparable  to  the  monoclonal  antibody  anti-Flag  (Fig.  3.2), 
indicating an high efficiency and high signal to noise ratio. 
 
 
3.3 pUL53 during HCMV infection.  
To perform the analysis of pUL53 during infection, a novel highly specific antibody was 
generated as detailly described in Materials and Methods. IIF assays performed on mock- and 
infected HELFs confirmed that, at late stages of infection (96-120h p.i.), pUL53 localizes 
mostly at the nuclear rim forming aggregates, previously described as “punctuate patches” 
(Dal Monte et al., 2002), although at minimal levels in the cytoplasm of HCMV infected 
cells(Fig.  3.3a).  The  analysis  of  the  phases  of  HCMV  infection  showed  that  pUL53  is 
undetectable in cells at early stages of infection and appears at 48h pi, at the nuclear rim with 
a slightly discontinuous distribution (Fig. 3.3b). The formation of distinct aggregates follows 
at  later  stages  (Fig.  3.3b’),  suggesting  a  temporal  organization  of  pUL53  expression  and 
localization.  
To confirm pUL53 distribution, nuclear and cytoplasmic extracts were obtained from mock- 
and infected HELFs and analyzed by Western Blotting: a clear band at about 42 kDas was 
strongly detectable in infected nuclear fractions, while a very low signal was detectable in 
infected cytoplasmic extracts (Fig. 3.4). Nuclear and cytoplasmatic extracts of mock-infected 
HELFs did not show any positivity. 
 
 
3.4 pUL53 colocalizes with nuclear lamina modifications. 
To further investigate the role of pUL53 during HCMV infection, co-staining experiments of 
pUL53 with d the different components of nuclear lamina were performed on HELFs late in 
infection, when the viral protein is organized in nuclear aggregates. 
The analysis revealed that the HCMV-induced invaginations in lamin B and in lamin A/C 
correspond to pUL53 aggregates on the nuclear rim(Fig. 3.5a – b, respectively).   31
To further characterize the invaginations and distortions observed, a monoclonal antibody 
raised  against  a  phosphorylated  epitope  at  the  N-terminus  of  lamin  A/C,  called  SW2-30 
(Radsak), has been used for co-staining IIF assay with anti-pUL53 anti-serum. Differently 
from lamin A/C, its N-terminal phosphorylated form presented, in mock-infected cells, an 
irregular and sometimes punctuate distribution, associated to the nuclear boundary. Infected 
cells  resulted  strongly  affected:  the  overall  fluorescence  signal  resulted  decreased,  but 
aggregates  of  phospho-lamin  A/C  were  detectable  at  the  nuclear  rim  co-localizing  with 
pUL53 punctuate patches (Fig. 3.5c). 
 
3.5 pUL53 does not co-immunoprecipitate with nuclear lamins 
To investigate if a strong interaction exists among pUL53 and nuclear lamina components, an 
immunoprecipitation has been performed on lysates of nuclear extracts of mock- and infected 
HELFs,  using  the  anti-pUL53  anti-serum.  The  viral  proteins  has  been  efficiently 
immunoprecipitated (Fig. 3.6), but both lamin A/C and lamin B were detectable only in the 
lysates lanes (Fig. 3.6c and Fig. 3.6b, respectively), indicating co-immunoprecipitation did 
not occurr. 
 
3.6 Singularly expressed pUL53-Flag localizes into the nucleus of transfected cells. 
To study the behaviour out of the viral contest, pUL53 has been expressed as a fusion protein 
with  the  epitope  Flag  in  COS7  cells.  IIF  assays  have  revealed  a  wide-spread  nuclear 
distribution with a low cytoplasmic staining, in contrast with the observations during infection 
(Fig. 3.7a). WB analysis on lisates of mock- and trasfected cells has confirmed the predicted 
molecular weight of about 41 kDas (Fig. 3.7b). 
 
 
3.7 Singularly expressed pUL50V5 localizes into the cytoplasm of transfected cells.  
pUL50 has been studied during transfection in COS7 cells, when singularly expressed as a 
fusion protein with epitope V5. IIF analysis showed the protein localizes predominantly in the 
cytoplasmic compartment and in perinuclear area, with a predominant ER pattern(Fig. 3.8a), 
in accordance with the predictions. The putative molecular weight of about 43 kDas has been 
confirmed by WB analysis on lysates of mock- and transfected COS7 cells (Fig. 3.8b). 
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3.8  pUL50V5  and  pUL53Flag  interact  at  the  nuclear  rim  of  transfected  cells  and  co-
immunoprecipitate.  
As  the  observations  of  the  localization  of  pUL53  during  infection  and  when  singularly 
expressed showed such a discrepancy, pUL53 has been co-expressed with pUL50V5 in COS7 
cells to study a potential interaction between them. IIF assays has revealed a complete re-
localization of both protein at the nuclear rim with the formation of aggregates (Fig. 3.9a), 
resembling the pattern of pUL53 observed in HCMV infected cells. The interaction has been 
further investigated by immunoprecipitation assay, that revealed pUL50V5 and pUL53Flag 
are able to interact and co-immunoprecipitate (Fig. 3.9b). All these data indicate pUL50 and 
pUL53 interact and need each other to acquire a  punctuate distribution at the nuclear rim, that 
is the physiological organization of pUL53 during viral infection. 
 
3.9 pUL53 sequence analysis. 
Sequence  analysis  of  pUL53,  performed  manually  and  using  several  on-line  softwares, 
revealed important putative characteristics of the viral protein:  
- 1 putative nuclear localization signal (NLS) with sequence RERRSALRSLLRKRRQR
27 at 
the N-terminus that could be responsible of its translocation into the nucleus when singularly 
expressed. 
- 1 C-terminal region with two sequences highly rich in basic aminoacids, typical of nuclear 
export signals (NESs): VTLNIVRDHVVISVL(230-244) and VKIDVTILQRKIDEMDI (253-
269)  (basic  aminoacids  are  underlined).  Manual  analysis  individuated  other  two  short 
sequences,  rich  in  leucine  LTLHDL(59-64)  and  LELKYL(74-79),  at  the  N-terminus, 
downstream the NLS. 
To  study  the  role  all  these  characteristics  on  the  behaviour  of  pUL53  (Fig.  3.10a),  the 
corresponding domains have been cloned singularly and expressed as fusion proteins with 
GFP, to analyse them in fixed and living cells. Six different plasmids were generated (see 
Table 2.2), encoding fusion proteins  (Fig. 3.10b) between N-terminal GFP and  
−  pUL53 wild type (residues 2-376); 
−  N-terminus of pUL53 ( residues 2-29), containing the putative NLS; 
−  pUL53 lacking the N-terminus (residues 30-376), containing the putative NESs, but not 
the NLS; 
−  pUL53 lacking the C-terminus with the putative NES (residues 2-242) 
−  pUL53 lacking both the N-terminus with the NLS and the C-terminus (residues 30-242) 
−  C-terminal domain of pUL53(residues 220-376).   33
3.10  Analysis  of  the  localization  pUL53  domains  as  fusion  proteins  with  GFP:  pUL53 
contains a functional nuclear localization signal (NLS) at the N-terminus. 
Classic approaches to identify an NLS are the generation of deletions corresponding to the 
signal sequence in the protein of interest and the generation of fusion proteins between the 
putative NLS with reporter proteins, such as β-galactosidase and GFP, that when singularly 
expressed  have  cytoplasmic  and  ubiquitous  localization,  respectively.  In  this  study,  the 
putative NLS of pUL53 has been expressed as a fusion protein with GFP, transfecting COS7 
cells with the plasmid pDEST53-UL53(2-29) and the localization has been observed both in 
fixed and living cell: GFP(2-29) is localized into the nucleus, accumulating frequently in the 
nucleoli and the signal in the cytoplasm is almost undetectable, indicating pUL53 NLS is 
functional ( Fig. 3.11b and 3.12b, respectively). 
The  analysis  has  been  performed  also  expressing  the  plasmids  pDEST53-UL53(2-242), 
encoding  for  N-terminal  GFP  fused  with  pUL53,  deleted  of  the  hydrophobic  C-terminal 
domain but still containing the putative NESs and pDEST53-UL53(2-376) encoding for N-
terminal GFP fused with full-length pUL53: both proteins displayed the same localization 
pattern of GFP-UL53(2-29) (Fig. 3.11a-3.12a and Fig. 3.11c-3.12c, respectively), indicating 
the NLS is able to translocate into the nucleus also proteins with a higher molecular weight. 
To  confirm  the  N-terminal  NLS  is  responsible  of  pUL53  nuclear  distribution,  pDEST53-
UL53(30-376) encoding the N-terminal deletion mutant of pUL53 as a fusion protein with 
GFP has been expressed in COS7 cells and observed by fluorescence microscopy on living 
and fixed cells. The expected result was the exclusion of the fusion protein from the nuclear 
compartment, as free diffusion through the membrane is allowed only for small proteins ( the 
cut-off is about 50 kDas), while, for large proteins, a NLS is required. Despite the relatively 
molecular weight (about 66 kDas) and the absence of the N-terminal NLS, GFP-UL53(30-
376) showed an ubiquitous distribution (Fig. 3.11d-3.12d).  
 
3.11  Analysis  of  the  localization  pUL53  domains  as  fusion  proteins  with  GFP:  pUL53 
contains nuclear export signals (NESs). 
Primary sequence analysis of pUL53 revealed the presence of  one sequence rich in basic 
aminoacids, typical of nuclear export signals (NES), located at the C-terminus of the viral 
protein. Moreover, other two short leucine-rich sequences are present at the N-terminus. To 
study the functionality of these sequences, pUL53 domains have been expressed in COS7 
cells as fusion protein with GFP in presence or not of a specific nuclear export inhibitor, 
Leptomycin  B,  and  the  analysis  has  been  performed  by  CLSM  on  living  cells  and  using   34
ImageJ software. Ratio between nuclear and cytoplasmic fluorescence (Fn/c) revealed GFP-
UL53(2-376) full-length is significantly sensitive to the inhibitor of the nuclear export (Fig. 
3.13); the same  result has been obtained for GFP-UL53(30-376) and  GFP-UL53(30-242), 
indicating that the C-terminal putative NES is functional. Surprisingly, also GFP-UL53(30-
242) showed a significant increase of Fn/c value after treatment, indicating the two sequences 
individuated by manual analysis could act as NESs.  
The analysis could not be performed for the proteins containing the N-terminal domain,  but 
lacking  of  the  C-terminus,  GFP-UL53(2-29)  and  GFP-UL53(2-242),  as  the  nuclear 
fluorescence  was  too  intense  with  respect  to  the  cytoplasmic  one,  preventing  an  accurate 
calculation  of  the  Fn/c  values.  However,  this  observation  suggests  that  the  two  NES-like 
sequences at the N-terminus are not sufficiently strong to confer cytoplasmic translocation in 
the presence of the NLS and in the absence of the C-terminal region. 
 
 
3.12  pUL50 sequence analysis. 
Similarly  to  pUL53,  also  pUL50  primary  sequence  has  been  analyzed  to  identify  its 
characteristic domains. On-line softwares revealed the presence of a cluster of hydrophobic 
aminoacids,  indicated  as  a  putative  transmembrane  domain,  located  at  the  C-terminus 
(residues 359-381) (Fig. 3.14). 
To study the role of the putative characteristics of pUL50 (Fig. 3.15a), the corresponding 
domains have been cloned singularly and expressed as fusion proteins with GFP and analyzed 
in fixed and living cells by fluorescence micoscopy. Four plasmids have been generated (see 
Table 2.2), encoding fusion proteins (Fig. 3.15b) between N-terminal GFP and  
−  pUL50 full length (residues 2-397); 
−  pUL50 deleted of the first 70 aminoacids ( residues 71-397),but containing the putative 
transmembrane region; 
−  pUL50 deleted of the C-teminal transmembrane domain( residues 2-358); 
−  C-terminal transmembrane domain of pUL50 (residues 215-397). 
 
 
3.13 Analysis of the localization pUL50 domains as fusion proteins with GFP in living and 
fixed cells.  
pUL50  domains  fused  with  GFP  have  been  expressed  in  COS7  cells  and  analyzed  by 
fluorescence  microscopy  in  living  and  in  fixed  cells.  Like  pUL50V5,  GFP-UL50(2-397)   35
displayed  a  typical  RE  pattern  with  a  cytoplasmic  localization,  associated  to  the  nuclear 
membrane (Fig. 3.16-3.17a). A similar distribution resulted for both GFP-UL50(71-397) and 
GFP-UL50(215-397), confirming the transmembrane domain is located at the C-terminus of 
the protein (Fig. 3.16-3.17 b and c, respectively). In particular, UL50(215-397) showed a 
strong association with the cellular membranes. In contrast, GFP-UL50(2-358), lacking of the 
C-terminal  domain,  showed  an  ubiquitous  distribution,  with  a  slight  accumulation  in  the 
nucleus and the occasional formation of small intranuclear speckles (Fig. 3.16-3.17d). 
  
 
3.14 Analysis of the interaction between  pUL50 and pUL53 by fluorescence assay on living 
and fixed cells. 
To  study  pUL50  and  pUL53  interaction  and  individuate  the  domains  responsible  of  their 
binding, COS7 cells have been transfected with the constructs encoding the protein fragments 
as fusion proteins with GFP and DsRed2 and observed by microscopy on living cells. 
Initially, DsRed2-UL53(2-376) full-length has been co-transfected with the different domains 
of  pUL50  fused  with  GFP.  The  analysis  showed  DsRed2-UL53  co-localizes  with  GFP-
UL50(2-397) in punctuate patches at the nuclear rim and with GFP-UL50(2-358), as both of 
them are dispersed into the nucleus (Fig. 3.18 a-b).  In contrast, GFP-UL50(71-397) and 
GFP-UL50(215-397) are retained in the cytoplasmic compartment, while DsRed2-UL53(2-
376) maintains its nuclear distribution, displaying the absence of co-localization (Fig. 3.18 c-
d). These data suggest that the  domain of pUL50 to bind pUL53 resides at the N-terminus, as 
the deletion of the first 70 aminoacids is sufficient to abolish their co-localization. 
The  reverse  experiment  has  been  performed  co-transfecting  COS7  cells  with  DsRed2-
UL50(2-397)  full-length  in  combination  with  pUL53  fragments  fused  with  GFP.  The 
observations  showed  that  DsRed2-UL50(2-397)  co-localizes    forming  aggregates  at  the 
nuclear boundary with GFP-UL53(2-376) (Fig. 3.19a), as expected; forms aggregates in the 
cytoplasm  and  at  the  nuclear  rim  with  GFP-UL53(30-376)  (Fig.  3.19d)  and  with  GFP-
UL53(30-242) (Fig. 3.19e), while seems to co-localizes in the same cytoplamic compartment 
with  GFP-UL53(220-376)  without  a  strict  association  (Fig.  3.19f).  GFP-UL53(2-242) 
displayed a distribution mostly in the nucleus, but a interaction at the nuclear rim, forming 
small aggregates with DsRed2-UL50(2-397) was detectable(Fig. 3.19c). In contrast, no co-
localization is detectable in cells co-tranfected with DsRed2-UL50(2-397) and GFP-UL53(2-
29), as pUL50 appeared distributed in the cytoplasm and the N-terminal pUL53 domain only 
inside the nucleus(Fig. 3.19b).   36
All these data suggest the N-terminus of pUL53 is not required to bind pUL50 and that the 
domain immediately downstream (as showed by GFP-UL53(2-242) is already sufficient to 
establish an interaction. The results about GFP-UL53(220-376) were not clear as displayed 
colocalization without any indication of interaction (the proteins did not change their original 
distribution). 
All these observations were performed also on fixed cells by IIF, using different plasmids: 
pc53Flag  instead  of  pBKdsRed2CMV-UL53(2-376)  and  pcDNA-UL50V5  instead  of 
pBKdsRed2CMV-UL50(2-397). The results were completely superimposable. (Fig. 3.20 and 
Fig. 3.21, respectively) 
 
 
3.15 Analysis of pUL50-pUL53 interaction by co-immunoprecipitation assay. 
To  confirm  the  data  obtained  by  microscopy  on  living  cells  and  IIF  and  study  in  depth 
pUL50-pUL53 interaction, COS7 cells were transfected with the same different combinations 
of vectors (using pc53Flag and pcDNA-UL50V5 instead of pBKdsRed2CMV-UL53(2-376) 
and pBKdsRed2CMV-UL50(2-397), respectively) and the cell lysates were used to perform 
immunoprecipitation  assays.  The  analysis  by  WB  of  the  immuno-  and  co-immuno-
precipitated proteins confirmed that: 
pUL50V5 interacts with GFP-UL53(2-376) full length, GFP-UL53(30-376), GFP-UL53(2-
242)  and  GFP-UL53(30-242),  but  not  with  GFP-UL53(2-29)  and  GFP-UL53(220-376), 
indicating that the N-terminal and C-terminal domains of pUL53 are not necessary to bind 
pUL50  (Fig.  3.22);  the  essential  binding  domain  of  pUL53  is  comprised  between  the 
aminoacids 30 and 220; pUL53Flag co-immuniprecipitates with GFP-UL50(2-397) and GFP-
UL50(2-358),  but  not  with  GFP-UL50(71-397)  and  GFP-UL50(215-397  (Fig.  3.23) 
confirming the binding domain of pUL50 to pUL53 is included in the first 70 residues. 
 
 
3.16 The complex pUL50-pUL53 induces nuclear lamina modifications and co-localizes 
with the alterated sites during transfection  
The remarkable alterations of nuclear lamins observed during infection, co-localizing with the 
aggregates of pUL53, and the observation of interaction and co-localization between pUL50 
and pUL53 reproducing the same pattern at the nuclear rim, reported for pUL53, opened the 
question if the viral proteins were able to induce those modifications even out of the viral 
contest, during transfection. To perform this study, COS7 cells were transfected singularly   37
with the plasmids GFP-UL53(2-376) and GFP-UL50(2-397) singularly and to co-expressed 
pUL50  and pUL53 the  plasmids GFP-UL53(2-376) and pcDNA-UL50V5 were used. The 
samples have been analyzed by IIF for lamin B, lamin A/C, phospho-lamin A/C.  
When singularly expressed, pUL50 did not determine any significant alterations on lamin B 
(Fig.3.24a);  similar  results  have  been  obtained  for  lamin  A/C,  both  in  its  not-  and 
phosporylated form, a part from a partial and occasional mislocalization in the cytoplasm of 
transfected cells(Fig.3.24b and c, respectively). 
Singularly expressed GFP-UL53(2-376) showed occasionally showed to cause a dissolution 
of both lamin B and lamin A/C. Moreover, phospho-lamin A/C showed a decreased staining 
at the nuclear rim (Fig.3.25a, b and c, respectively). 
The  sample  co-expressing  GFP-UL53(2-376)  and  pUL50V5  gave  results  completely 
superimposable with the observations during infection: in contrast with their homogeneous 
pattern in untransfected cells,  both lamin B and lamin A/C showed an irregular staining, with 
formation of invaginations corresponding to the aggregates of GFP-UL53(2-376) (Fig. 3.26a 
and b). In contrast, phospo-lamin A/C displayed a decrease of overall signal in co-transfected 
cells, as observed during infection, but the aggregates less frequently co-localized with the 
complex of transfected proteins, indicating their only expression is unsufficient to reproduce 
the same pattern (Fig. 3.26c). 
 
 
3.17 UL53 ORF can be  post-transcriptionally silenced by RNA interference. 
To  study  the  effects  of  the  silencing  of  UL53  on  viral  cycle  and  on  HCMV  induced 
modifications  of  nuclear  lamina  during  infection,  silencing  of  the  gene  expression  was 
necessary. UL53 ORF is inverted in HCMV genome sequence with respect to adjacent genes 
and shares about 50 nucleotides with UL54 ORF, encoding for the viral DNA polymerase. 
Moreover, polyadenilation signal of other genes are localized in UL53 sequence. For these 
reasons, the manipulation of HCMV genome and deletion of UL53 gene was not considered a 
good choice for gene silencing. 
Another options was represented by post-transcriptional gene silencing by RNA interference 
(RNAi) . To perform RNAi directed against UL53 transcript, pG-SUPER plasmid [142, 149] 
has been used (Fig. 2.1): this vector, after the insertion of the sequence directed against the 
gene of interest, produces a small hairpin RNA able to silence the target transcript. It also 
encodes for GFP, as marker of transfection.   38
Three  construct  have  been  generated:  the  plasmids,  called  pG-SUPER-UL53-224,  pG-
SUPER-UL53-757 and pG-SUPER-UL53-782 have different target sequences on UL53 gene 
(see Table 2.3) 
HELFs were transfected with the constructs separately and infected the day after. 120h post-
infection, cells were fixed and stained for pUL53, to verify if the silencing occurred, and the 
glycoprotein gN, to individuate HCMV positive cells at late time post-infection, as gN has 
been  reported  to  be  a  late  protein.  The  results  have  been  contrasting:  the  constructs  pG-
SUPER-UL53-757 and pG-SUPER-UL53-782 displayed a poor efficiency in silencing the 
expression of pUL53, as the viral protein was still detectable in GFP- and gN-positive cells, 
even if the intensity of pUL53-staining showed a decrease (Fig.3.27c and d, respectively); on 
the  contrary,  pG-SUPER-UL53-224  exhibited  a  good  interfering  activity  as  shown  in 
(Fig.3.27e), with respect to the negative control transfected with pG-SUPER and infected. 
This result is promising for further analysis of the role of pUL53, during infection.  
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4. DISCUSSION 
 
 
 
This study has been focused on fundamental events of HCMV replicative cycle: the capsidic 
maturation  through  the  nuclear  envelope  to  enter  the  cytoplasm  and  the  modifications  of 
involved cellular components. As previously reported, the egress of virions from the nuclear 
compartment is essential to reach the cytoplasm, which is the final site of maturation and 
tegumentation; however, during this passage, viral particles face a strong obstacle, consisting 
in a thick protein network that underlines the INM, called nuclear lamina, that opposes to the 
egress. 
Our  results  show  that,  during  HCMV  infection,  lamins,  the  main  components  of  nuclear 
lamina,  undergo  remarkable  modifications:  analysis  by  IIF  assay  of  mock-  and  infected 
fibroblasts, co-stained for  the major components of nuclear lamina, lamin B and lamin A/C  
and the viral glycoprotein gB as a marker of infection, showed that both lamins assume an 
irregular  distribution  at  the  nuclear  rim  of  infected  cells,  with  respect  to  the  smooth  and 
homogenuous  pattern  observed  in  mock-infected  cells,  and  form  deep  invaginations, 
increasing in number with the progression of infection . 
In  the  herpesvirus  family,  two  highly  conserved  viral  products,  pUL31  and  pUL34,  are 
described as essential “guides” for the passage through the INM: the two viral proteins form a 
complex at the INM and are strictly correlated to nuclear envelope alterations.  
Thus,  the  study  has  been  focused  on  pUL53  and  pUL50,  homologous  to  pUL31  and 
pUL34,respectively, and their role in viral infection. 
To perform analysis during infection, a novel, highly specific antibody has been raised against 
the purified protein. The antibody α-pUL53 allowed to follow the expression of the viral 
protein during infection: pUL53 is weakly detectable at 48h post-infection, while, at later 
stages, is strongly expressed and localizes at the nuclear rim, at first with a discontinuous but 
homogenous pattern, later forming aggregates or “punctuate patches”, suggesting a temporal 
rearrangement of the protein at the nuclear boundary.   40
The involvement of pUL53 in lamina rearrangement has been investigated by IIF on mock- 
and infected HELFs: pUL53 aggregates resulted to co-localize with lamin B and lamin A/C 
invaginations at the nuclear rim, suggesting a role for this protein in inducing such alterations. 
Modification of lamin  A/C was further studied using  a monoclonal antibody versus a N-
terminal phosphorylated form of lamin A/C, in which the phosporylated epitope is located 
within the first 417 aminoacids: in uninfected cells, phospho-lamin A/C is distributed at the 
nuclear  boundary  with  a  clear  even  if  inhomogeneous  pattern,  while  in  infected  pUL53-
positive  HELFs,  a  decrease  of  the  intesity  of  total  phospho-laminA/C  staining  has  been 
detected, consistent with the previously published data that reported a quantitative decrease of 
this form of phosporylated lamin A/C in HCMV infected fibroblasts, as shown by Western 
blotting; interestingly, the phosphorylated lamin appeared to form small aggregates strongly 
co-localizing with pUL53 patches. 
These data support the observation performed with lamin A/C and B and indicate lamins 
undergo  alterations  in  structure    and  phosphorylation  at  the  same  sites  where  pUL53  is 
distributed and the degree of damage increases with the progression of the infection and the 
organization of pUL53 in larger aggregates. 
Immunoprecipitation (IP) assays have been performed to evaluate if an interaction among 
pUL53 and lamina components exists: IP against pUL53 did not reveal a stable interaction 
nor with lamin B neitehr with lamin A/C. 
The next step in this study has been the characterization of pUL53 out of the viral contest. 
The protein has transiently been expressed in mammalian cells and the analysis of its sub-
cellular localization by  IIF  revealed a different pattern, as  compared to the one observed 
during  infection:  when  singularly  expressed,  pUL53  displays  a  wide-spread  nuclear 
distribution with a low cytoplasmic staining. 
This result induced to enlarge the study to pUL50, homolog of HSV-1 pUL34 that is the 
counterpart of pUL31, homolog to HCMV pUL53: pUL34 and pUL31 are reported to need 
each other to interact and co-localize at the nuclear rim of infected cells, where the complex 
can direct the egress of nuclear virions. 
pUL50 is predicted to be a type II trans-membrane protein, similarly to the other members of 
pUL34  family,  and,  as  expected,  IIF  analysis  on  singularly  transfected  mammalian  cells 
showed  that  the  protein  localizes  predominantly  in  the  cytoplasmic  compartment  and  in 
perinuclear area, with a predominant ER pattern. 
To  study  their  potential  interaction,  pUL50  an  pUL53  have  been  co-expressed  and  heir 
localization  has  been  analyzed  by  IIF,  that  showed  both  proteins  undergo  a  marked  re-  41
localization at the nuclear rim with the formation of aggregates, resembling the pattern of 
pUL53 observed in  HCMV infected cells. The interaction has been confirmed by  IP and 
Western blotting. 
All the results reported are consistent with data in literature that describe the homolog protein 
to HCMV pUL50, pUL34, as a cytoplasmatic product with a ER-like localization and the 
homolog to HCMV pUL53, pUL31 as nuclear protein; also for the homologs, the interaction 
is  necessary  and  sufficient  for  the  re-localization  at  the  nuclear  boundary.  In  contrast  to 
pUL50 and pUL53, that organize in distinct aggregates, pUL31 and pUL34 exhibit a smooth 
pattern  on  the  nuclear  rim,  differently  from  pUL50  and  pUL53  that  organize  in  distinct 
aggregates. Notably, it has been  also reported that pUL31 and pUL34 form aggregates only 
in  absence  of  a  non-essential  viral  encoded  kinase,  called  Us3,  that  is  supposed  to 
phosphorylate preferentially pUL34: in HCMV an homolog kinase to Us3 is not present and it 
is possible to postulate that in this case the virus evolved without this accessory product. 
As, during infection, nuclear lamins modification are detectable mainly when native pUL53 
forms aggregates at the nuclear rim, the analysis of  nuclear components has been performed 
also during transient expression of pUL50 and pUL53, singularly and simultaneously. 
When singularly expressed, pUL50 did not determine any significant alterations on lamin B; 
similar results have been obtained for lamin A/C, both in its not- and phosporylated form, a 
part from a partial and occasional mislocalization in the cytoplasm of transfected cells. 
In contrast, pUL53-positive cells showed an occasional dissolution of both lamin B and lamin 
A/C. Moreover, phospho-lamin A/C showed a decreased staining at the nuclear rim. 
In  cells co-expressing pUL50  and pUL53 in form of aggregates at the nuclear boundary, 
laminA/C and lamin B displayed a pattern superimposable to the distribution observed during 
viral  infection:  lamin  A/C  and  B  showed  an  irregular  staining  and  invaginations,  in 
correspondence  of  the  punctuate  patches  of  pUL50-pUL53  complex.  Phospho-lamin  A/C 
displayed  a  decrease  in  fluorescence  intensity,  but  only  a  partial  co-localization  with  the 
complex was detectable. 
The present data suggest pUL50 and pUL53 might have a direct and fundamental role in 
modifying  nuclear  lamina  and  that  their  co-expression  is  sufficient  to  induce  structural 
alterations, comparable to the ones occurring during HCMV infection. As over-expression of 
pUL50 and pUL53 was not sufficient to determine the re-arrangement of phospho-lamin A/C 
as induced upon infectionN-term phosphorylated lamin A/C did not show, out of the viral 
contest, the same pattern observed in infected cells, we can hypothesize that, during infection, 
other factors can be involved in the biochemical alterations of lamina, acting in sinergy with   42
pUL50 and pUL53. This hypothesis is also consistent with the observation during infection 
that pUL53 and nuclear lamins lack of a stable interaction. 
The results obtained are in agreement with data published for the homologous proteins to 
pUL50 and pUL53 in other herpesviruses, that  report the homolog proteins are able to induce 
conformational  changes  at  the  nuclear  rim  and  to  recruit  cellular  protein  kinases  to 
phosphorylate  nuclear lamina components. 
The  primary  sequences  of  pUL50  and  pUL53  have  been  analyzed  to  characterize  their 
putative properties and to map the domains responsible of their reciprocal interaction and, as a 
consequence, of  their re-localization at the nuclear rim, where the complex can carry out its 
functions. 
pUL53  presents  a  putative  nuclear  localization  signal  at  the  N-terminus  (residues 
RERRSALRSLLRKRRQR
27 ), while at the C-terminus a  region highly rich in basic residues 
has been individuated, suggesting the presence of a nuclear export signal (NES). Moreover, 
other two short basic sequences are located at the N-terminal domain, downstream the NLS. 
pUL50 present a putative transmembrane domain at the C-terminal end. 
These putative properties have been studied expressing the correspondent domains as fusion 
proteins with GFP and analyzing both living and fixed cells by fluorescence microscopy. Both  
full-length proteins fused with GFP displayed a pattern superimposable to the one observed 
when expressed as fusion protein with smaller tags (Flag for pUL53 and V5 for pUL50). The 
expression  of    GFP-UL53(2-29),  carrying  only  the  N-terminal  domain  of  pUL53,  has 
demonstrated that the putative NLS is functional as the protein displayed a completely nuclear 
distribution, with frequent nucleolar accumulation. Also GFP-UL53(2-242) showed a nuclear 
pattern, but it was excluded from the nucleoli. Consistent with the finding that pUL53 NLS is 
licalized at its N_terminus, GFP-UL53(30-376) distributed both in the nucleus and in the 
cytoplasm.  The  central  fragment  GFP-UL53(30-242)  and  the  C-terminal  fragment  GFP-
UL53(220-376)  localized  ubiquitously,  but  mainly  in  the  cytoplasm  of  transfected  cells, 
indicating the potential presence of NES in their sequence. 
To analyze the putative NESs, transfected cells have been treated with Leptomycin B (LMB), 
a specific inhibitor of CRM1, which is an exportin that mediates the translocation of proteins 
carrying NESs, from the nucleus to the cytoplasm. Living transfected cells, treated and un-
treated  with  LMB,  have  been  analyzed  by  CLSM  and  tocalculate  nuclear  to  cytoplasmic 
fluorescence  ratio(Fn/c).  GFP-UL53(2-376)  full-length,  GFP-UL53(30-242)  and  GFP-
UL53(220-376) showed a significant Fn/c increase upon treatment with LMB, indicating that 
the  NES-like  sequences  individuated  by  primary  sequence  analysis  are  functional.  The   43
analysis could not be performed for the proteins containing the N-terminal domain but lacking 
of the C-terminus, as the nuclear fluorescence was too intense with respect to the cytoplasmic 
one, preventing an accurate calculation of the Fn/c values. 
The analysis on living and fixed cells of pUL50 domains fused with GFP revealed that GFP-
UL50(2-397)  full-length,  GFP-UL50(71-397),  lacking  of  the  N-term  domain  and  GFP-
UL50(215-397),  carrying  only  the  C-terminus  of  pUL50  localize  in  the  cytoplasm  of 
transfected  cells,  with  a  typical  ER  distribution.  In  contrast,  GFP-UL50(2-258)  localized 
ubiquitously, with a slight accumulation in the nucleus and and the occasional formation of 
small intranuclear speckles. 
All these data suggest pUL53 is a shuttling protein with a functional NLS at the N-terminus of 
its sequences, responsible of its nuclear localization and NES sequences at the C-terminus. 
The analysis of the sequence of pUL50 suggested only the presence of a transmembrane 
region  at  the  C-terminus  (residues  358-381),  whereas  nor  NLS  neither  NES  putative 
sequences were identified.  
Our fluorescence analysis confirmed pUL50 carries a C-terminal transmembrane region as the 
domain (215-397) is necessary and sufficient to confer a ER localization pattern to GFP. 
 The  analysis  of  pUL50  fragments  fused  with  GFP  has  dem  nstrated  the  presence  of  a 
transmembrane  region  at  the  C-terminus,  that  is  necessary  to  acquire  the  right  cellular 
localization. 
The expression of the different fragments of pUL50 and pUL53 fused with GFP has been 
used  also  to  study  their  interaction  domains  in  living  and  fixed  cells  by  fluorescence 
microscopy. Firstly, all pUL50 fragments fused with GFP have been expressed with pUL53 
full length fused with DsRed2 (DsRed2-UL53(2-376)): GFP-UL50(2-397) full length showed 
co-localization and interaction with DsRed2-UL53(2-376), as expected; co-localization has 
been  observed  also  for  GFP-UL50(2-258),  while  both  GFP-UL50(71-397)  and  GFP-
UL50(215-397), lacking of the N-terminus of pUL50 did not show any co-localization. 
The  same  analysis  has  been  performed  expressing  DsRed-UL50(2-397)  full  length  in 
combination  with  pUL53  fragments  fused  with  GFP:  only  GFP-UL53(2-29)  failed  to  co-
localized  with  DsRed-UL50(2-397),  even  if  for  GFP-UL53(220-376)  the  co-localization 
seemed more due to a distribution in the same compartment, than a real interaction. 
The  same  experiments  were  performed  in  fixed  cells  by  IIF,  expressing  pUL53Flag  and 
pUL50V5,  instead  of  DsRed2-UL53(2-376)  and  DsRed-UL50(2-397),  respectively.  The 
results in fixed cells were superimposable to the data obtained with living cells.   44
Finally,  co-IP  assays  were  performed  on  lysates  of  cells  co-expressing  pUL50V5  in 
combination with pUL53 fragments fused with GFP and pUL53Flag in combination with 
pUL50 fragments fused with GFP to confirm the observations in fluorescence microscopy.  
The  results  allowed  to  identify  the  region  of  both  proteins  required  for  the  reciprocal 
interaction, in residues 1-70 and 30-242 for pUL50 and pUL53, respectively. 
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5. CONCLUSIONS 
 
 
 
Human  Cytomegalovirus  infection  causes  severe  pathologies  in  newborn  babies  and 
immunocompromised patients, worldwide. The pharmacological therapies available contrast 
viral  replication  by  blocking  the  activity  of  the  viral  encoded  DNA  polymerase.  The 
compounds with such anti-viral activity are indeed highly effective, but the emergency of new 
resistant  viral  strains  is  growing,  raising  the  necessity  to  develop  alternative  antiviral 
treatments to associate with the classic ones. In this contest, the comprehension of essential 
mechanisms for a productive viral cycle and the research of new antiviral targets are acquiring 
importance.  
In this work, we performed a study of pUL50 and pUL53, two still uncharacterized proteins 
of Human Cytomegalovirus (HCMV), whose homologs in other herpesviruses are reported to 
have a fondamental role in viral maturation, promoting the egress of the newly formed virions 
from the nucleus to the cytoplasm of the host cell.  
In parallel,  also nuclear lamins, the major cellular components constituting nuclear lamina, 
have been examined: lamins, in association with other nuclear proteins, form a thick proteic 
meshwork  underlying  the  inner  nuclear  membrane  and,  in  the  viral  contest,  represent  an 
physical obstacle to the viral egress from the nuclear compartment.  
Observations performed during infection showed marked rearrangements of nuclear lamins: 
lamin B and A/C displayed a ruffled distribution and deep invaginations at the nuclear rim 
and a N-terminal  phosphorylated form of lamin A/C showed a decrease in infected cells, with 
the formation of inhomogeneous aggregates at the nuclear rim. . 
The  novel  high  specific  anti-serum  anti-pUL53,  which  has  been  raised  in  this  work,  has 
allowed to observe the localization of the viral protein in punctuate patches at the nuclear rim 
and that its aggregates strongly co-localize with the alterations on nuclear lamina, suggesting 
its involvement in inducing such modifications. 
The analysis by IIF and Western blotting of pUL53 and its counterpart, pUL50, out of the 
viral contest, has shown that, when singularly expressed, pUL53 localizes into the nucleus 
and  pUL50 in the cytoplasm, with a typical ER pattern, while when co-expressed, the two   46
protein are able to interact and to re-localize at the nuclear rim, resembling the distribution 
pUL53 acquires during infection. This data demonstrates pUL50 and pUL53 are able form a 
complex  and their interaction  is necessary and sufficient to each other to aquire a distribution 
in aggregates at the nuclear boundary, which is the physiological pattern of pUL53. 
The analysis of nuclear lamins in the presence of pUL50 and pUL53, expressed singularly or 
co-expressed  out  of  the  viral  contest,  strongly  suggests  the  two  HCMV-encoded  proteins 
might have a role in the alterations of nuclear lamina. At the same time, the observation that 
their complex is not sufficient to determine the modifications in the form of phopshorylated 
lamin A/C revealed in infected cells and that , during infection, they do not establish a stable 
interaction with lamins suggests the hypothesis that other viral factors can be involved and act 
in sinergy with pUL50 and pUL53. 
This study has also demonstrated that pUL53 presents a functional nuclear localization signal 
(NLS)  at  its  N-terminus  (RERRSALRSLLRKRRQR
27)  and  two  functional  nuclear  export 
sequences  (NES)    at  the  C-terminus  (VTLNIVRDHVVISVL
244  and 
VKIDVTILQRKIDEMDI
269),  indicating  pUL53  is  a  shuttling  protein  and  that  pUL50 
presents a transmembrane region in its C-terminal domain (residues 359-381).  
Moreover, the analysis of different portions of the two viral proteins has allowed to indentify 
the  domains  of  their  reciprocal  interaction,  in  residues  1-70  and  30-242  for  pUL50  and 
pUL53, respectively. 
Moreover, RNA interference experiments directed against pUL53 transcript during infection 
indicated that UL53 ORF can be efficiently silenced during infection, opening the way to new 
investigations on the mechanisms of viral maturation 
This  study  provides  a  characterization  of  pUL50  and  pUL53  properties,  interaction,  both 
reciprocal  and  with  the  host  cells  nuclear  proteins  that  is  promising  to  understand  the 
mechanism of viral egress from the nucleus. 
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Table 2.1. List of the oligonucleotides used in this study for the generation of expression vectors. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
OLIGO 
NUCLEOTIDE 
SEQUENCE 
( Sequences are indicated 5’-3’; Att sites are underlined; STOP codons are in italics.) 
 
PRIMERS for UL53   
UL53-U21  ATGTCTAGCGTGAGCGGCGTG 
UL53-L21  AGGCGCACGAATGCTGTTGAG 
AttB1-UL53-1  GGGGACAAGTTTGTACAAAAAAGCAGGCTTGTCTAGCGTGAGCGGTGTCCGCACGCCGCG 
AttB1-UL53-86  GGGGACAAGTTTGTACAAAAAAGCAGGCTTGGCCAGCAAAGTGGCGTCGACGGTGAA 
AttB1-UL53-242  GGGGACAAGTTTGTACAAAAAAGCAGGCTTGATGAAGATGGCCATCACGGGCAA 
AttB1-UL53-677  GGGGACAAGTTTGTACAAAAAAGCAGGCTCAGACTACAGCGTCACGCTCAACATCG 
AttB2-UL53-87  CGCAAGCGCCGCCAACGCGAGCTGTGAACCCAGCTTTCTTGTACAAAGTGGTCCCC 
AttB2-UL53-240  CCGAACTGGAGCTCAAGTACCTTAACTAGACCCAGCTTTCTTGTACAAAGTGGTCCCC 
AttB2-UL53-726  AACATCGTGCGCGACCACGTCGTTATCAGCTGAACCCAGCTTTCTTGTACAAAGTGGTCCCC 
AttB2-UL53-1128  GTTTCTCAACAGCATTCGTGCGCCTTGAACCCAGCTTTCTTGTACAAAGTGGTCCCC 
 
PRIMERS for UL50 
UL50-U18  ATGGAGATGAACAAGGTT 
UL50-L16  GTCGCGGTGTGCGGAG 
AttB1-UL50-1  GGGGACAAGTTTGTACAAAAAAGCAGGCTTGGAGATGAACAAGGTTCTCCATC 
AttB1-UL50-215  GGGGACAAGTTTGTACAAAAAAGCAGGCTTTATCTTTAAAAACACTGGCTG 
AttB1-UL50-647  GGGGACAAGTTTGTACAAAAAAGCAGGCTCTCCCCCTCCTCCTCCTCGTCA 
AttB1-UL50-1073  GGGGACAAGTTTGTACAAAAAAGCAGGCTGGCTGCCCGCGCGCTTTGCGACTCTG 
AttB2-UL50-213  CACAGACCACGTGCCTTGTTGAACCCAGCTTTCTTGTACAAAGTGGTCCCC 
AttB2-UL50-651  CTCTCGGACCGCATCTCCCTGAACCCAGCTTTCTTGTACAAAGTGGTCCCC 
AttB2-UL50-1074  CGCGACCGCAGTCTGGGCCGTGGTGAACCCAGCTTTCTTGTACAAAGTGGTCCCC 
AttB2-UL50-1191  ACACGCTCCGCACACCGCGACTGAACCCAGCTTTCTTGTACAAAGTGGTCCCC  
 
 
 
 
Table 2.2. Constructs generated by Gateway Technology, used in this study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.3. Plasmids for UL53 RNA interference. The target sequences were chosen distributed in 
all UL53 gene. Oligos consist in a 19-nucleotides sequence separated by a short spacer from its 
reverse complement and were inserted in pG-SUPER vector. 
 
 
 
Constructs generated by Gateway Technology 
 
pDONOR207-UL53(2-376)  pDEST53-UL53(2-376) 
pBKdsRed2CMV-UL53(2-376) 
pDONOR207-UL53(2-29)  pDEST53-UL53(2-29) 
pDONOR207-UL53(2-242)  pDEST53-UL53(2-242) 
pDONOR207-UL53(30-376)  pDEST53-UL53(30-376) 
pDONOR207-UL53 (30-242)  pDEST53-UL53 (30-242) 
pDONOR207-UL53 (220-376)  pDEST53-UL53 (220-376) 
   
pDONOR207-UL50(2-397)  pDEST53-UL50(2-397) 
pBKdsRed2CMV-UL50(2-397) 
pDONOR207-UL50(2-358)  pDEST53-UL50(2-358) 
pDONOR207-UL50(71-397)  pDEST53-UL50(71-397) 
pDONOR207-UL50(215-397)  pDEST53-UL50(215-397) 
STARTING 
NUCLEOTIDE 
IN UL53 ORF 
 
TARGET SEQUENCE 
 
PLASMID 
224  GCTCAAGTACCTTAACATG  pG-SUPER-UL53-224 
757  TCAAGATCGACGTGACTAT  pG-SUPER-UL53-757 
782  ACGCAAGATTGACGAGATG  pG-SUPER-UL53-782 7. FIGURESFig.1.1. Schematic drawing of Human Cytomegalovirus structure. (Adapted from
Marko Reschke).Fig.1.2. Schematic representation of Human Cytomegalovirus replication cycle. N = 
nucleus; C = cytoplasm; ER = endoplasmic reticulum;G = Golgi(Adapted from Marko
Reschke).Fig.1.3. Schematic view of the nuclear envelope. Lamin A/C and B underline INM and 
estabilish interactions with several nuclear membrane  proteins and  chromatin (Adapted
from Foisner et al., Journal of Cell Science, 2001).Fig. 1.4.  Schematic representation of  nucleocytoplasmic transport. (A)  Nuclear
import occurs when IMP1, either alone or through IMP, recognizes an NLS on the cargo 
protein in the cytoplasm (1) and mediates the docking of the complex to the NPC (2) 
followed by translocation into the cell nucleus. Binding of RanGTP to IMP1 (3) results in 
the cargo being released into the nucleus (4). (B) Nuclear export occurs when cellular
export receptors, such as the IMP homologue CRM-1, recognize a NES on the cargo 
protein in the presence of RanGTP (1) and mediate the docking of the complex to the 
NPC and its translocation to the cytoplasm (2). Upon hydrolysis by Ran of GTP to GDP 
(3), facilitated by Ran GTPase-activating protein (not shown), the cargo is released into
the cytoplasm (4).(Adapted from Alvisi et al., Drug Resistance Update, 2006.)
Fig. 1.5  Chemical structure of  Leptomycin B. Leptomycin B  (LMB)  is a  specific
inhibitor of nuclear export, binding covalently CRM1 and preventing its interaction with
proteins provided of NESs.Fig.1.6.  Schematic representation of  lamins. (a)  Structure of  lamin proteins.  Main
characteristics are four central rod domains (1A, B, 2A, B), flanked by a globular head and 
tail domain. In the tail domain a nuclear localization signla can be identified, as well as a 
CaaX motif,  which is present in  both B-type and  A-type lamins,  other than lamin C. 
(Adapted from Broers et al., Physiol Rev,  2006);  (b)  Different lamin isotypes found in 
mammalian tissues. Lamin A, C, A∆10 and C2 result from differentialsplicing of LMNA
gene; lamins B2 and B3 originate from LMNB2 gene ans lamin B1 is the only transcript of 
LMNB1 gene. (Adapted from Moir et al.,Cellular and Molecular Cell Science, 2001).
(a) (b)Fig. 1.7.  Schematic representation of  herpevirus egress from the  nucleus. Newly
replicated herpesvirus DNA is inserted into preformed capsids in the nucleus of the host cell. 
To reach the inner nuclear membrane (INM) of the nuclear envelope, the subviral particles
must transit through the physical barrier of the nuclear lamin meshwork. The viral protein
UL34 (pink) of HSV-1 (the homolog of M50/p35 in murine CMV) is a type II transmembrane
protein that is localized at the INM in infected cells via its interaction with UL31 (turquoise), 
a viral protein in the nucleus. UL34 and UL31 recruit protein kinase C (PKC) to the nuclear
membrane,  resulting in  an increase in  phosphorylation of  the  lamins.  This causes partial
disruption of the lamin network, thereby facilitating envelopment of subviral particles at the 
INM.  The  particles acquire some  of  their tegument proteins and  a  primary envelope by
budding through the INM. They then lose their primary envelope as they bud through the 
outer nuclear membrane (ONM) of the nuclear envelope and are released into the cytoplasm. 
The  DNA-containing capsids move to the  Golgi complex,  where they acquire additional
tegument proteins and a mature envelope. Finally, they travel in Golgi-derived vesicles to the 
plasma membrane, where they are released from the host cell.Fig. 3.1.  HCMV  infection induces remarkable modifications on  nuclear lamina. 
Infected human fibroblast have been co-stained for gB, as marker of infection, and (a)
lamin B or (b) lamin A/C. Both lamins showed an irregular staining with an aberrant
formation of invaginations.
Lamin B gB merge
(a)
Lamin A/C gB merge
(b)pc53Flag + +
_ _
Anti-Flag Anti-pUL53
pUL53Flag
Fig. 3.2 Test of the specificity of the anti-serum raised against pUL53 in this study.
The  antiserum  against  pUL5  and  the  controls  have  been  prelevated and  tested  for 
specificity by WB on lysates of mock- and transfected COS7 cells with the plasmid 
pc53Flag.  Anti-pUL53  anti-serum  displayes a  reactivity  similar  to  the  commercial 
monoclonal antibody anti-Flag+ + _ _ HCMV
pUL53
Nuc Cyt
Fig. 3.3. pUL53 during HCMV infection: IIF assay on infected HELFs. 
(a) Fixed cells were co-stained for gN, as marker of infection, and pUL53 thanks to the novel
antibody raised for this study: pUL53 localizes at the nuclear boundary, forming aggregates. 
(b) Fixed cells were stained for pUL53  at  different times after  infection:  at  48-72h  post-
infection, pUL53 shows mainly a slighty discontinuous pattern at the nuclear rim, while, 120h 
post-infection, distinct aggregates of the viral protein are clearly detectable.
(a)
(b)
Fig. 3.4. pUL53 during HCMV infection: WB analysis on nuclear and cytoplasmic
extracts of infected HELFs. Nuclear and cytoplasmic extracts were obtained from mock-
and  infected  HELFs and  analyzed  by  WB  assay:  a  clear  band  at  about  42  kDas was 
strongly detectable in infected nuclear fractions, while a very low signal was detectable in 
infected  cytoplasmic extracts.  No  signal  was  detectable  in  nuclear  and  cytoplasmatic
extracts of mock-infected HELFs.
pUL53 gN merge
pUL53 merge DAPI
(b’)pUL53
pUL53
pUL53
merge
merge
merge
Lamin B
Lamin A/C
P-lamin A/C
Fig. 3.5.  pUL53  colocalizes with the  modifications occurring on  nuclear lamina 
during HCMV infction. Infected human fibroblast have been co-stained for pUL53 
with (a) lamin B, (b) lamin A/C or (c) phospho-lamin A/C. pUL53 co-localizes with the 
invaginations of lamin B and lamin A/C and with the aggregates of phospho-lamin A/C.
(a)
(b)
(c)Fig. 3.6. pUL53 and nuclear lamins do not strongly interact.  Lysates of nuclear
extract of mock- and infected HELFs were used to immunoprecipitate pUL53 with anti-
pUL53  anti-serum.  pUL53  has been immunoprecipitated,  but not nuclear lamins
indicating the absence of a strong interaction between nuclear lamina and viral protein.
(b)
pUL53
Lamin A/C
+ + _ _
HCMV
IP anti-pUL53 lysates
(a)
+ + _ _ HCMV
pUL53
Lamin B
IP anti-pUL53 lysatespUL53Flag merge DAPI
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Fig 3.7. pUL53Flag localizes in the nucleus of transfected cells. (a) In IIF analysis, 
pUL53Flag shows a wide-spread nuclear distribution with a low cytoplasmic staining, in 
contrast with the observations during infection; (b) WB analysis on lisates of mock- and 
trasfected cells has confirmed the predicted molecular weight of about 41 kDas
pcUL53Flag + _
pUL53Flag
WB anti-FlagDAPI pUL50V5 merge
(a)
(b)
Fig 3.8. pUL50V5 localizes in the cytoplasm of transfected cells. (a) In IIF analysis, 
pUL50V5localizes predominantly in the cytoplasmic compartment and in perinuclear
area, with a predominant ER pattern ; (b) WB analysis on lisates of mock- and trasfected
cells has confirmed the predicted molecular weight of about 43 kDas
pcDNA3-UL50V5 + _
pcUL50V5
WB anti-V5pc53Flag
pcDNA-UL50V5 +
+ +
+ _
_
_
_
IP anti-Flag
pUL53Flag pUL50V5
+
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+ _
_
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_
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Fig. 3.9. pUL50 and pUL53 interact and colocalize at the nuclear rim. (a) IIF assay on 
COS7 expressing both pUL53Flag and pUL50anti-Flag V5 revealed the proteins interact and 
completely re-localize at the nuclear rim; (b) IP assay on lysates of mock- and co-transfected
COS7 cells indicates the two viral proteins interact directly.
pUL53Flag pUL50V5 merge
(a)
(b)pUL53 (1-376)
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Fig. 3.10.  Schematic representation of pUL53  properties.  (a)  pUL53  wild  type
presents a putative N-terminal NLS (red) (residues 10-27) and putative NESs (blu) at 
its N-terminus (residues 59-64 and 74-79) and C-terminus (residues 230-244 and 253-
269 (b) different domains of pUL50 expressed as fusion proteins with GFP, used in 
this study.(a) GFP-UL53
(2-376)
(b) GFP-UL53
(2-29)
(c) GFP-UL53
(2-242)
(d) GFP-UL53
(30-376)
(e) GFP-UL53
(30-242)
(f) GFP-UL53
(220-376)
Fig. 3.11. Imaging of living cells expressing pUL53 different domains fused with GFP. 
(BF: brightflield). The N-terminal NLS mediated the protein nuclear localization (a, b, c); 
pUL53 domains lacking of N-terminus localizes ubiquitously (d) or in the cytoplasm(e, f).
BF mergeBF merge
(a) GFP-UL53
(2-376)
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(c) GFP-UL53
(2-242)
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Fig. 3.12. Imaging of fixed cells expressing pUL53 different domains fused with GFP. 
Nuclear staining has been performed with DAPI. The results are superimposable to the one 
obtained with living cells (Fig. 3.11)Fn/c
GFP-UL53
(220-397)
GFP-UL53
(30-242)
GFP-UL53
(30-376)
GFP-UL53
(2-397)
+ + + + _ _ _ _ LMB
Fig. 3.13. Statistical analysis of Fn/c ratio of pUL53 domains localization in absence or 
presence of Leptomycin B (LMB). Images have been analiyzed using ImageJ software and 
data using Sigma Plot 9.0 software. The columns represent the mean values +/- standard 
errors. Significative differences are indicated with (*)
*
*
*
*Fig. 3.14. The on-line software THMM predicts a transmembrane region at the 
N-terminus of pUL50 (residues 358-381)
pUL50
GFP-UL50(2-397)
GFP-UL50(2-358)
GFP-UL50(71-397)
GFP-UL50(215-397)
Fig. 3.15.  Schematic representation of pUL50  properties.  (a)  pUL50  wild  type
presents a putative transmembrane region at its C-terminus (residues 358-381); (b) 
different domains of pUL50 expressed as fusion proteins with GFP, used in this study.
(a)
(b)(a) GFP-UL50
(2-397)
(b) GFP-UL50
(71-397)
(c) GFP-UL50
(2-258)
(d) GFP-UL50
(215-376)
Fig. 3.16. Imaging of living cells expressing pUL50 different domains fused with GFP. 
All the fusion proteins containing the C-terminal domain localize in the cytoplasm with a ER 
pattern (a, b, c); GFP-UL50 (215-376) is strongly associated to cellular membranes (c).
GFP-UL50, lacking of the C-terminus, localizes in the all cell, accumulating in the nucleus
and forming occasionally intanuclear speckles.(a) GFP-UL50
(2-397)
(b) GFP-UL50
(71-397)
(c) GFP-UL50
(2-258)
(d) GFP-UL50
(215-376)
Fig. 3.17. Imaging of fixed cells expressing the different pUL50 domains fused with
GFP. Nuclear staining has been performed with DAPI. The results are superimposable to the 
one obtained with living cells (Fig. 3.1?)(a) GFP-UL50 
(2-397)
(b) GFP-UL50
(2-358)
(c) GFP-UL50
(71-397)
(d) GFP-UL50
(215-397)
DsRed2-
UL53(2-376) merge
3.18 Analysis of pUL50 binding domain to pUL53 in living cells:  DsRed2-UL53(2-376) 
full length has been espressed with all the different domains of pUL50 fused to GFP. Living
cells were analyzed by fluorescent microscopy.3.19 Analysis of pUL53 binding domain to pUL50 in living cells. DsRed2-UL50(2-
397) full length has been espressed with all the different domains of pUL53 fused to
GFP. Living cells were analyzed by fluorescent microscopy.
DsRed2-
UL50(2-397) merge
(a) GFP-UL53
(2-376)
(b) GFP-UL53
(2-29)
(c) GFP-UL53
(2-242)
(d) GFP-UL53
(30-376)
(e) GFP-UL53
(30-242)
(f) GFP-UL53
(220-397)3.20 Analysis of pUL50 binding domain to pUL53 in fixed cells:  pUL53Flag has been
espressed with all the different domains of pUL50 fused to GFP. Fixed cells were analyzed
by IIF using anti-Flag monoclonal antibody.
(a) GFP-UL50 
(2-397)
(b) GFP-UL50
(2-358)
(c) GFP-UL50
(71-397)
(d) GFP-UL50
(215-397)
merge p53Flag3.21 Analysis of pUL53 binding domain to pUL50 in fixed cells:  pUL50V5 has been
espressed with all the different domains of pUL53 fused to GFP. Fixed cells were analyzed
by IIF using anti-V5 monoclonal antibody.
(a) GFP-UL53
(2-376)
(b) GFP-UL53
(2-29)
(c) GFP-UL53
(2-242)
(d) GFP-UL53
(30-376)
(e) GFP-UL53
(30-242)
(f) GFP-UL53
(220-397)
pUL50V5 mergeFig. 3.22. Identification of the pUL53 domain of interaction with pUL50 by IP. (a)  IP 
has been performed on lyates of cells expressing pUL50V5 in combination with the different
pUL53 domains fused to GFP. The pUL53 domain interacting with pUL50 resides within the 
200 central aminoacids.Fig. 3.23. Identification of the pUL50 domain of interaction with pUL53 by IP. (a)  IP 
has been performed on lyates of cells expressing pUL53Flag in combination with the 
different pUL50 domains fused to GFP. The pUL50 domain interacting with pUL53 resides
within the 70 first aminoacids.Lamin B merge GFP-UL50(2-397)
(a)
(b)
(c)
P-lamin A/C merge GFP-UL50(2-397)
Lamin A/C merge GFP-UL50(2-397)
Fig. 3.24. Analysis by IIF of  lamins in cells expressing GFP-UL50(2-397). pUL50 
does not determine any significant alterations on lamin B or A/C, a part from a partial 
and  occasional  co-localization  with  lamin A/C  Both  in  its  phosphorylated and 
phosphorylated form in the cytoplasmic compartment.Fig. 3.25. Analysis by IIF of  lamins in cells expressing GFP-UL53(2-376). GFP-
UL53(2-376) shows occasionally to cause a dissolution of both lamin B (a)and lamin
A/C(b) . Moreover, phospho-lamin A/C shows a partial decreased staining (c)
GFP-UL53(2-376) Lamin A/C merge
GFP-UL53(2-376) P-lamin A/C merge
GFP-UL53(2-376) Lamin B merge
(a)
(b)
(c)GFP-UL53(2-376)
+pUL50V5 P-lamin A/C merge
GFP-UL53(2-376)
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Fig. 3.26. Analysis by IIF of  lamins in cells expressing GFP-UL53(2-376) and 
pUL50V5. The interaction between pUL50 and pUL53 is indicated by the formation
of  aggregates of  GFP-UL53(2-376)  at  the  nuclear rim. In  pUL50and  pUL53  co-
expressing  cells,  both  lamin B  and  lamin A/C  show  an  irregular  staining,  with 
formation of invaginations corresponding to the aggregates of GFP-UL53(2-376) (a) 
and (b); phospo-lamin A/C displays a decrease in overall signal, but the aggregates 
rarely co-localize with GFP-UL53(2-376) punctuate distribution (c).Fig. 3.27.  RNA  interference against HCMV  UL53  transcript. HELFs have been
transfected at  day  0  with the  construct pG-SUPERUL53-224  and  infected at  day  1  with
HCMV AD169. Cells were fixed 120h post-infection and revealed by IIF for pUL53 and gN. 
(a) Untransfetcted cells; (b) transfected with pG-SUPER; (c) transfected with pG-SUPER-
UL53-757;  (d)  transfected with pG-SUPER-UL53-782;  (e)  transfected with pG-SUPER-
UL53-224.
GFP gN pUL53 merge
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